



HAL
open science

Martini 3 building blocks for Lipid Nanoparticle design

Lisbeth Ravnkilde Kjølbye, Mariana Valério, Markéta Paloncýová, Luís Borges-Araújo, Roberto Pestana-Nobles, Fabian Grünewald, Bart Bruininks, Rocío Araya-Osorio, Martin Šrejber, Raul Mera-Adasme, et al.

► **To cite this version:**

Lisbeth Ravnkilde Kjølbye, Mariana Valério, Markéta Paloncýová, Luís Borges-Araújo, Roberto Pestana-Nobles, et al.. Martini 3 building blocks for Lipid Nanoparticle design. *Journal of Chemical Theory and Computation*, 2025, <10.26434/chemrxiv-2024-bf4n8>. <hal-04745118>

HAL Id: hal-04745118

<https://hal.science/hal-04745118v1>

Submitted on 20 Oct 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

1 Martini 3 building blocks for Lipid Nanoparticle design

2 LISBETH R. KJØLBYE¹, MARIANA VALÉRIO^{1,2,3†}, MARKÉTA PALONCÝOVÁ^{4†},
3 LUÍS BORGES-ARAÚJO^{1,2,3†}, ROBERTO PESTANA-NOBLES^{1,5}, FABIAN GRÜNEWALD⁶,
4 BART M. H. BRUININKS⁷, ROCÍO ARAYA-OSORIO⁸, MARTIN ŠREJBER⁴,
5 RAUL MERA-ADASME⁸, LUCA MONTICELLI¹, SIEWERT J. MARRINK⁹,
6 MICHAL OTYEPKA^{4,10}, SANGWOOK WU^{11,12*}, PAULO C.T. SOUZA^{1,2,3*}

7 ¹*Molecular Microbiology and Structural Biochemistry (MMSB, UMR 5086), CNRS and University of Lyon,*
8 *Lyon, France.*

9 ²*Laboratoire de Biologie et Modélisation de la Cellule, CNRS, UMR 5239, Inserm, U1293, Université*
10 *Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, 46 allée d'Italie, 69364, Lyon, France.*

11 ³*Centre Blaise Pascal de Simulation et de Modélisation Numérique, Ecole Normale Supérieure de Lyon, 47*
12 *allée d'Italie, 69364, Lyon, France.*

13 ⁴*Regional Centre of Advanced Technologies and Materials, Czech Advanced Technology and Research*
14 *Institute (CATRIN), Palacký University Olomouc, Šlechtitelů 27, Olomouc 779 00, Czech Republic.*

15 ⁵*Laboratorio de Simulación Molecular y Bioinformática, Centro de Investigación en Ciencias de la Vida*
16 *(CICV), Universidad Simón Bolívar, Carrera 59 59-65, Barranquilla 080002, Colombia.*

17 ⁶*Heidelberg Institute for Theoretical Studies (HITS), Heidelberg, Germany.*

18 ⁷*Department of Physics, University of Helsinki, P.O. Box 64, FI-00014 Helsinki, Finland.*

19 ⁸*Departamento de Química, Facultad de Ciencias, Universidad de Tarapacá, Av. Gral. Velasquez 1775,*
20 *Arica, Chile.*

21 ⁹*Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, the Netherlands.*

22 ¹⁰*IT4Innovations, VŠB - Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00,*
23 *Czech Republic.*

24 ¹¹*PharmCADD, 1102 ho, 60, Centum jungang-ro, Haeundae-gu, Busan, 48059, Republic of Korea.*

25 ¹²*Department of Physics, Pukyong National University 48513, Busan, Republic of Korea.*

26 *Corresponding authors: s.wu@pharmcadd.com, [paulo.telles_de_souza@ens-lyon.fr](mailto: paulo.telles_de_souza@ens-lyon.fr)

27 †These authors contributed equally.

28 **Abstract:** Lipid nanoparticles (LNPs) represent a promising platform for advanced drug
29 and gene delivery, yet optimizing these particles for specific cargos and cell targets poses a
30 complex, multifaceted challenge. Furthermore, there is a pressing need for a more compre-
31 hensive understanding of the underlying technology. Experimental studies are costly and often
32 provide low-resolution information. Molecular dynamics (MD) simulations allow us to study
33 these particles at a higher resolution, enhancing our understanding. However, studying these
34 systems at atomic resolutions is both challenging and computationally expensive, as well as
35 time-consuming. Coarse-grained (CG) models, such as Martini 3, are positioned as promising
36 tools for studying LNPs. To enable CG-MD studies of LNPs, accurate and validated models of
37 their components are needed. Here, we present a substantial extension of the Martini 3 library of
38 lipids, covering the most important LNP components, including over a hundred of ionizable lipid
39 (IL) models, along with natural occurring sterol models and PEGylated lipid models. We further-
40 more present initial protocols for screening fusion efficacy across different lipid formulations
41 and for constructing whole LNPs at CG resolution, enabling future studies of these nanoparticles.

42

43 1. Introduction

44 The interest in lipid nanoparticles (LNPs) has increased tremendously because of their large
45 potential in vaccines as a delivery platform. However, the understanding of this technology is still
46 substantially lacking and remains a multivariate problem, making it difficult to investigate and
47 decouple specific variables. An LNP typically consists of five major components, an ionizable

48 lipid (IL), a sterol, a helper phospholipid, polyethylene glycol conjugated (or PEGylated) lipids,
49 and cargo. In addition to optimizing each component, the relative ratio between them can
50 also be optimized depending on the cargo, target cell specificity or stability, not to mention
51 the assembly process [1, 2]. Although experimental studies can explore certain variations
52 under certain conditions, extensive screening of ratios and components is neither easy nor
53 cheap, especially when non-commercially available lipids need to be synthesized and tested [3].
54 Additionally, experiments often lack high-resolution structural and dynamical information about
55 the architecture and phase changes of LNPs under different pH values [4, 5].

56 The currently accepted mode of action for LNP delivery is that, upon injection into the
57 bloodstream, a corona shell is formed around the particle, where the APO E peptide is an essential
58 component in addition to albumin. APO E is responsible for LNP endocytosis into the cell. The
59 resulting endosome formed with the LNP inside will then mature, resulting in a pH drop from 7
60 to around 6-5. Upon the pH drop, several of the ILs in the LNP become protonated which is
61 believed to induce structural changes in the LNP that enable particle fusion with the endosomal
62 membrane and the eventual release of its cargo into the cytosol. In the case of mRNA cargo, as
63 in the COVID vaccines, the mRNA is then transcribed by the ribosome [6, 7].

64 Several LNP properties are optimized to improve their potency, such as particle and cargo
65 stability in storage and/or blood, fusion efficacy in relation to endosomal escape, or even target-cell
66 specificity [2, 6, 8]. Regarding LNP stability, PEGylated lipids are often used to improve particle
67 'stealthiness' in terms of stability in the blood, and to help maintain a certain particle size while
68 in storage [9]. The main instability, however, has been identified as originating from the cargo,
69 whether RNA or DNA [10]. Given the extensive experimental data readily available on RNA
70 degradation rates, AI-based approaches are already a reality for the computational design of
71 new RNA sequences [11]. However, the situation is different for LNP lipid composition and
72 its influence on vaccine efficacy. Likely due to the lack of large, curated databases, there are
73 currently no well-established AI-based protocols for optimizing lipid composition, despite its
74 clear significance in enhancing LNP properties. Only initial attempts at *in silico* screening lipid
75 compositions have been made [12].

76 An additional issue with current LNP technology is that, only a very small percentage of
77 the cargo, in the case of RNA, actually reaches the cytosol of target cells. One of the biggest
78 hurdles is the cargo endosomal escape. To optimize this crucial process, it is necessary to
79 enhance LNP fusion with the endosome while avoiding excessive fusogenicity with other lipid
80 compartments [13]. Understanding the pH-dependent phase behavior of LNPs is essential for
81 optimizing endosomal escape [1]. Despite several studies that attempt to shed light on the matter,
82 a comprehensive understanding is still lacking due to the multivariate nature of LNPs [5, 14–18].
83 Overall, the literature still lacks a deep molecular and functional understanding of LNP technology.
84 Although some small details have been revealed, the puzzle remains incomplete and requires
85 further integration of experimental and computational approaches to achieve a clear understanding
86 of the whole picture.

87 Molecular dynamics (MD) simulations are a valuable tool for studying, in detail, the packing
88 behavior and organization of LNPs, as well as their endosomal release process. Combining
89 MD studies of LNPs with available experimental data could provide valuable high resolution
90 structural insight that would be otherwise inaccessible [15, 19, 20]. For example, MD simulations
91 have suggested that optimizing the packing of the Moderna ILs around the RNA nucleobases via
92 π - π stacking may enhance cargo stability [21]. Such computational strategies could be used to
93 further optimize and advance LNP technology. However, the sheer complexity and size of LNPs
94 puts them beyond the reach of traditional spatial and time scales currently accessible to atomistic
95 MD simulations, posing challenges in terms of computational resources. This is where coarse
96 grained (CG) MD simulations can play a major role, alleviating these limitations [1, 22, 23].

97 The Martini CG force field (FF) [24, 25] is a widely used CG model, in particular for MD

98 simulations involving lipids in complex biological environment [26] and their interplay with
99 other biomolecules and synthetic materials [25,27]. Martini enhances sampling efficiency and
100 reduces system complexity by representing two to four non-hydrogen atoms, along with their
101 associated hydrogens, as a single CG bead. This model employs a building block approach and
102 integrates both bottom-up and top-down methods to derive bonded and non-bonded interactions,
103 respectively. A sub-selection of previous works have highlighted the possibilities for delivery
104 systems being studied with with Martini force field, examples ranging from simulating the escape
105 of DNA from a lipoplex [23] to studying the lipid nano-emulation for vitamin delivery [28].
106 Some work has also been on LNPs, studying the core and pH dependency [22,29]. The latest
107 version, Martini 3, significantly improves interaction accuracy and greatly expands chemical
108 space coverage [30] making it a promising new tool for designing and optimizing LNPs, which
109 was not as feasible with earlier models [1]. In this work, we introduce an extensive and new
110 Martini 3 library that includes ILs, sterols, and PEGylated lipids. Additionally, we provide
111 detailed protocols for exploring fusion processes, investigating pH-dependent phase behavior of
112 LNPs, and constructing and analyzing whole LNPs in solution or during interactions with target
113 membranes. This work aims to lay the foundation for computational design and screening of
114 LNP formulations using Martini CG MD simulations.

115 **2. Results**

116 *2.1. LNP lipid models*

117 2.1.1. Ionizable lipid parameterization - a fragment based approach

118 To build Martini 3 CG models of ionizable lipids, a building block approach was employed (Figure
119 1). This approach consists of modeling several IL fragments – representing various regions of the
120 IL, such as the headgroup, linker region or acyl chain – which can then be assembled to model
121 entire ILs (Figure 1). Not only does this simplify the parameterization process, but it also allows
122 researchers to use these fragment models to build other IL models or get inspiration for new
123 ones, making it easier to study different LNPs by changing specific chemical groups within the
124 lipids. The naming convention adopted for the two-tailed IL models consists of the two-letter
125 combination for the tails (typically used for phospholipids), followed by a two-letter combination
126 for the head/linker region. For the head, the first letter remains the same across protonation states,
127 while the second letter changes to "P" for the charged protonated state (see Figure 1A).

128 To obtain the necessary parameters for the IL CG models, atomistic MD simulations were
129 conducted for each fragment. These simulations provided the bonded parameters and solvent
130 accessible surface area (SASA) values essential for accurate model construction. In the absence
131 of experimental data for the fragments, we also used COSMO-RS, a quantum chemistry-based
132 method, to predict the thermodynamic properties [31]. This approach has consistently been
133 recognized as one of the best prediction tools for oil/water partitioning data [32,33]. An additional
134 advantage of COSMO-RS is its ability to predict logP for not only the octanol/water but also
135 for other partitioning systems, which is crucial for the chemical transferability of the Martini
136 CG models. In this work, we used all three gold standard partitioning systems employed in
137 Martini 3 parametrization: octanol/water, hexadecane/water, and chloroform/water. We also
138 ensured consistency across both the fragment library and the existing phospholipid library. For
139 some fragments, compromises on the CG partitioning free energy were necessary to maintain
140 consistency and transferability within the library. It is worth noting that COSMO-RS typically
141 has an mean absolute error (MAE) range of 2-3 kJ/mol [32,33], which justifies our preference for
142 maintaining internal consistency with the Martini bead assignment rather than perfectly matching
143 the free energies.

144 Figure 1B shows the matching of CG and atomistic SASA, indicating an excellent agreement,
145 which reflect not only the accurate fitting of bond distance but also the choices of bead sizes. The

146 overall comparison between COSMO-RS and Martini 3 CG partitioning free energies showed
147 a reasonable agreement with a $R^2 = 0.80$ and MAE = 6.4 kJ/mol (Figure 1C). The matching
148 between the approaches was worse for larger, branched hydrophobic fragments, such as some of
149 the linker fragments containing several carbons and one hydrophilic group such as an ester or
150 ether. These discrepancies are expected as experimentally it is impossible to accurately estimate
151 these values, with any predictions becoming less trustworthy [34]. Additionally, as already
152 mentioned, there is an inherent error of the COSMO-RS estimates. Therefore, the main focus for
153 selecting the types of beads was to maintain consistency between fragments, chemical groups,
154 and other Martini 3 lipid models. Hence, the difference in partitioning free energy between the
155 CG models and predicted values, is not an issue for the final IL models. The behavior of the ILs
156 was later compared with atomistic models to further validate the choices.

157 In total 15 head and 10 linker fragments were made along with 2 fragments for constructing
158 PEGylated lipids. When combined with the available tail parameters, this setup allows for the
159 generation of hundred of different lipids. As an example, we provided a total of 117 unique
160 coarse-grained (CG) models of ILs, each in both neutral and charged states (total of 234 parameter
161 files). Furthermore, additional IL models featuring branched tails were constructed, including
162 the well-known ALC-0315 and SM-102, which are used in Pfizer and Moderna vaccines,
163 respectively [35,36].

164 2.1.2. Validation of bonded terms from fragments when used as part of ILs

165 The bonded parameters obtained for the fragments were further validated with four ILs from the
166 literature, for which CHARMM36 parameters are available [20]. We focus on the two widely
167 known ILs, DLMC3 and DLKC2, which will henceforth be referred to as DUM3 / DUMP
168 and DUK2 / DUKP, depending on the protonation state, or simply MC3 and KC2. Using the
169 CHARMM36 FF [20,37], these two IL types were simulated in a IL:POPC bilayer (30:70 mol%)
170 during 1 μ s for both the fully charged and neutral state. The corresponding CG systems were
171 simulated for 1 μ s as well, and the bonded distributions were compared between the atomistic
172 and CG simulations. See Figure S2-11 for the SASA and bonded distributions for DUM3/MP
173 and DUK2/KP, the rest can be found on the GitHub (<https://github.com/Martini-Force-Field-Initiative/M3-Ionizable-Lipids/>). This comparison aimed to verify that the bonded parameters
174 derived from the OPLS fragment simulations match well with those obtained from whole ILs,
175 albeit obtained using a different atomistic force field. In addition to these ILs, Amber FF
176 simulations of Pfizer (ALC-0315) and Moderna (SM-102) from the work of Paloncová *et al.* [16]
177 were also used to cross-validate their CG equivalents. The bonded and SASA distributions
178 showed a good overlap between the atomistic lipid, fragment and coarse grained lipid model.
179

180 2.1.3. Increasing the Martini 3 LNP toolbox with sterols and PEGylated lipids

181 Optimizing LNPs presents a multi-variable challenge. Typically, the composition of LNPs
182 consists of a base mixture comprising an ionizable lipid, a sterol, a helper lipid like DSPC or
183 PE, and a PEGylated lipid. [4] Several studies have focused on optimizing the ionizable lipid,
184 with the emphasis on apparent pKa, fusion efficacy and biodegradability [38–40]. Other studies
185 have investigated the role of the helper lipid in LNP structure and fusion [41]. Recent studies
186 are now beginning to reveal the impact of replacing commonly used cholesterol with alternative
187 sterols, such as plant sterol β -sitosterol. These investigations demonstrate that such substitutions
188 not only alter LNP properties like shape and structure but can also markedly improve fusion
189 efficacy [42–44].




Fig. 1. Representing the fragment-based approach to construct several ionizable lipid models. A) The funnel illustrates the fragment-based approach and the step-by-step process for constructing an ionizable lipid. It begins with headgroup fragments and their corresponding names in the larger section of the funnel, followed by additional linker fragments that can be incorporated. Finally, the tails are attached to complete the lipid structure. B) Solvent Accessible Surface Area (SASA) for atomistic vs coarse grained fragments. C) COSMO-RS vs CG calculated partitioning free energies for the coarse grained fragments. D) The chemical structure of the ALC-0315 ionizable lipid is depicted, with the head, linker, and tails regions highlighted to correspond with the colors shown in the funnel above. Additionally, examples of other key components of a LNP are presented, including sterol, helper lipid, PEGylated lipid, and RNA cargo.

190 We expanded our library with four naturally occurring sterols (Ergosterol, Campesterol,
191 β -sitosterol, and Stigmasterol), modeled based on the new cholesterol model for Martini 3 [45].
192 The sterol models were simulated in DSPC bilayers and compared with cholesterol, ensuring a
193 correct trend in terms of packing, insertion, and melting temperature relative to the experimental
194 data. See Figure S12-24 in the supporting information for the bonded distributions along with
195 these properties mentioned above. In addition to sterols, we have also included PEGylated lipid
196 models in the Martini 3 LNP toolbox. Leveraging the versatility of Polyply, [46] adjustable PEG
197 head lengths are available, which could be combined with the Martini 3 tail library and with
198 fragments exclusively generated to facilitate the modeling of DMG-PEG and ALC-0159. As
199 an example, we provide a model of DMG-PEG 2000 and ALC-0159. It is important to note,
200 however, that the use of PEG in Martini 3 currently requires some adjustments in the interactions
201 between SN3r and charged (Q) beads [47].

202 2.2. Validation of the ionizable lipid models

203 2.2.1. Reproducing IL charge-dependent lamellar/oil lens behavior

204 Generally, in bilayer simulations involving helper lipids and different combinations of head/linker
205 and tail compositions from ILs, it is expected that neutral species will accumulate in the middle,
206 forming an oil lens between the two leaflets and leading to a significant increase in membrane
207 thickness. To demonstrate that our model can also capture this effect, we performed Martini
208 simulations of DLMC3 and DLKC2 (DUM3 / DUMP and DUK2 / DUKP) when mixed with
209 POPC (10:90, 20:80, and 30:70 IL:POPC mol%). CHARMM36 atomistic simulations were
210 performed of bilayers at the same concentrations of ILs for comparison. These analyses were
211 performed in either the fully charged or neutral state, representing low- and high-pH situations,
212 respectively.

213 Figure 2A and S25 shows the density across the bilayer normal for the DUM3/MP and
214 DUK2/KP headgroups in both the atomistic and corresponding CG systems. At low pH the
215 IL is assumed fully charged, while at high pH it is neutral. As confirmed by the snapshots
216 of the simulations highlighted in Figure 2B, the IL maintains a lamellar topology at low pH
217 (charged headgroup), while at high pH (neutral headgroup) it accumulates in between the POPC
218 leaflets, generating the expected oil lens. This behaviour aligns well with the knowledge in the
219 literature, where neutral MC3 and cholesterol are concluded to form an oil core within LNPs,
220 while multilamellar and inverse hexagonal phases are proposed to form under low pH when
221 ILs are charged [14, 18]. Additional results from atomistic simulations also indicate the same
222 behavior [19, 20].

223 Notably, the CG models of neutral MC3 (DUM3) and KC2 (DUK2) tend to aggregate
224 slightly more in the interleaflet region compared to the corresponding atomistic simulations.
225 Several parameterizations of MC3 (DUM3) with the CHARMM and Slipids force field have been
226 presented in the literature and compared to experimental data such as Neutron Reflectometry [48].
227 For the CHARMM parameters the accumulation of the neutral specie in the interleaflet is
228 underestimated. [48] The bilayer thickness of neutral MC3 in DOPC bilayers at 10 and 15 mol%
229 IL (50 mM NaCl, 288 K) was experimentally determined to be 41 ± 3 and 40 ± 3 Å [48]. For
230 comparison we simulated the same compositions of MC3:DOPC under the same conditions and
231 measured a bilayer thickness of 38.20 ± 0.27 and 39.61 ± 0.31 Å, respectively, aligning well with
232 the experimentally *in vitro* determined values. Hence the increased accumulation of the neutral
233 species observed in the CG simulations may not match entirely with the atomistic simulations
234 but rather appears to agree well with the *in vitro* experimental data. These findings validate our
235 model's ability to replicate the expected behavior across IL protonation states.

236 2.2.2. Expanding IL Model Validation: Effects of Headgroup, Linker, and Tail Variations

237 To further validate our IL models, we took advantage of our building block approach for
238 constructing ILs and extended our tests to a larger sub-selection of headgroups, linkers, and tails
239 in $15 \times 15 \text{ nm}^2$ IL:DSPC (50:50 mol%) bilayer patches. From these simulations, we calculated
240 the area per lipid (APL) and the hydrophobic thickness, specifically the distances between the two
241 leaflets excluding the polar headgroups. See Figure S26 for the head/linkers and tails under study
242 along with the APL and thickness values. The APL was only calculated for the charged species
243 that maintained the lamellar topology. A trend was observed across the lipid tails, with the DU
244 tail (CDDC CDDC) having the highest APL. The fully saturated tails DL and DS consistently
245 showed lower and similar APL across the lipid types (see Figure S26 for more details). This
246 trend aligns with observations in common phospholipids, where polyunsaturated tails exhibit
247 higher APL compared to saturated ones [49]. The choice between saturated and unsaturated tails
248 for LNP usage is a topic of discussion in the literature; unsaturated tails, despite being prone to
249 oxidation and presenting an instability issue, have demonstrated a significant improvement in
250 LNP transfection efficacy [50, 51].

251 2.2.3. pH-dependent phase behaviour reproduced

252 It has been suggested that LNP organization depends not only on their lipid composition and
253 cargo but also on pH of the environment. [5, 14, 43, 52]. LNPs containing siRNA or mRNA are
254 proposed to have a multilamellar [18] or inverse hexagonal / worm-like internal structure [5, 14],
255 respectively. The lamellar topology has been shown to only be maintained with charged MC3
256 (DUMP) based on SAXS (Small Angle X-ray Scattering) data [18]. The following question is
257 whether the same ILs can form an inverse hexagonal phase, given the right conditions, such as
258 pH [5].

259 Experimental studies [5, 14] have found that both MC3 and KC2 form an inverse hexagonal
260 phase at low pH with a hydration of around 7–12 water molecules per lipid. They also propose
261 that the core of LNPs consists of around 75 mol% IL and 25 mol% cholesterol. The presence of
262 cholesterol has previously been suggested to help maintain the inverted hexagonal phase of the
263 LNPs based on atomistic MD simulations [17]. The tests for formation of inverse hexagonal
264 phase were therefore performed with KC2 and MC3 in the presence of either DSPC or cholesterol.

265 Double bilayer systems were constructed of both MC3 (DUM3/DUMP) and KC2 (DUK2/DUKP)
266 with 10 mol% DSPC or with 25 mol% cholesterol and low hydration (around 7 water molecules
267 per lipid) and neutralizing ions, representing low and high pH, assuming fully charged or neutral
268 lipids, based on the experimental conditions in the work by Philipp *et al.* [5].

269 Indeed, both MC3 and KC2 form the inverse hexagonal phase in with both DSPC and
270 cholesterol, however only at low pH, assuming a plus one charge for all the ILs. The inverse
271 hexagonal phase does however not seem to depend on the presence or absence of either DSPC
272 nor cholesterol, see Figure 2C and D. An additional test was performed with only MC3 and KC2
273 at low pH, and in fact the inverse hexagonal phase was formed as well. The simulations reach the
274 same conclusion as obtained experimentally [5], that the phase is determined by the ionizable
275 lipid and not the helper lipid DSPC nor cholesterol.

276 At high pH, the neutral MC3 or KC2 does not form any topology resembling an inverse
277 hexagonal phase. In the presence of DSPC small inverse micelle pockets are formed, with the
278 same being observed for the cholesterol-containing systems, though there, the neutral IL mixes
279 with cholesterol and separates from the water phase completely, see Figure 2C and D. This aligns
280 well with experimental SAXS data [5, 14], suggesting that the parameters can indeed reproduce
281 the known pH-dependent phase behaviour of these ILs.




Fig. 2. A) Density of headgroups of MC3 (DUM3) and KC2 (DUK2) across the membrane normal at low and high pH. B) Snapshot of the bilayers containing MC3 (in orange) and POPC lipids (in purple) at high and low pH. C) Snapshots of systems containing MC3:Cholesterol (75:25) forming an inverted hexagonal phase and inverse micellar phase at low and high pH, respectively. D) Snapshots of systems containing MC3:DSPC:Cholesterol (50:40:10) forming an inverted hexagonal phase and inverse micellar phase at low and high pH, respectively. MC3 and MC3H lipids are shown in orange, DSPC in purple, cholesterol in pink and the water bead in cyan.

282 2.3. Towards *in silico* screening of LNP formulations: fusion assays

283 A large library of IL models can enable various studies, including the screening and character-
284 ization of different LNP lipid formulations, in terms of their packing, phase behaviour, and
285 fusiogenic behaviour against different membrane models. To illustrate the potential of this
286 IL model library and to propose an approach for assessing LNP efficiency, we focus here on
287 quantifying the fusiogenic properties of different formulations. For this purpose, we adapted
288 the protocol by Hub *et al.* [53] to perform Potential of Mean Force (PMF) fusion assays of
289 stalk formation between different LNP formulations and a plasma membrane model [54]. The
290 LNP interacting leaflet of this membrane is composed of (in mol%) 24 % POPC, 12 % PAPC,
291 2 % POPE, 6 % DIPE, 24 % DPSM and 31 % CHOL while the non-interacting leaflet contains
292 14 % POPC, 8 % PAPC, 5 % POPE, 16 % DIPE, 11 % DPSM, 28 % CHOL, 25 % PAPS, 2 % PAP6.
293 Additionally, we also studied the stalk formation between the LNP formulations and a membrane
294 model enriched with 10 mol % PAPS lipids in the LNP-interacting leaflet to better mimic the
295 compositional differences observed in the endosome. PAPS was also included in this leaflet
296 based on the hypothesis that anionic lipids, such as PS, could play an important role in the
297 transfection mechanism, and to better represent the increase in negatively charged lipid found in
298 late endosomes [55,56].

299 The initial barrier to membrane fusion is the formation of a hemifusion stalk, which should
300 be followed by the formation of a fusion pore [23,57,58], process not covered by our fusion
301 assays. Here we use the PMF method to calculate the free energy landscape of the fusion
302 intermediates, providing insights into the energetic barriers and stability of the stalk. Figure
303 3A presents a schematic overview of the process by which the LNP enters the cell and leads to
304 protein expression, with stalk formation highlighted in Figure 3B as the proposed initial barrier
305 for endosomal escape.

306 2.3.1. Acyl-chain dependent fusion efficacy

307 The experimental work by Sabnis *et al.* [36] marked a pivotal point in the optimization of the
308 IL chemistry, focusing on enhancing protein expression and subsequent fusion efficacy. From
309 the well-established MC3 lipid, they derived nine additional ILs. Compared to MC3, one
310 derivative performed worse (Lipid 2), while others exhibited significantly enhanced performance
311 (such as Lipid 10) in terms of protein expression. The distinctions between Lipid 2, 10, and
312 MC3 lie in increasing saturation and branching of the tails, coupled with the introduction of
313 an additional ester group, which makes Lipid 10 more biodegradable [36]. In an attempt to
314 reproduce these experimental trends, we performed a fusion PMF assay with bilayers mimicking
315 LNP formulations (IL:CHOL:DSPC at 50:40:10 mol% ratio), were MC3, Lipid 2, or Lipid 10
316 where the ILs studied, and a plasma membrane [54], as mentioned above.

317 These fusion PMFs (Figure3D) revealed a substantial decrease in the free energy of stalk
318 formation for Lipid 10 compared to MC3, and a slight increase for Lipid 2 compared to MC3,
319 consistent with the protein expression trend reported by Sabnis *et al.* [36]. Other studies have also
320 shown that replacing alkenes with alkanes and introducing esters and branching of the lipids tails
321 enhances delivery, since it helps in lipid protrusion, enabling the lipid to more easily overcome
322 the dehydration barrier between the two membranes, and thereby forming the stalk [59,60]. This
323 in turn helps to explain why Lipid 10 outperforms MC3 in the PMF assays, due to the increased
324 branching and introduction of an additional ester.




Fig. 3. Understanding the first stages of endosomal escape through PMFs of stalk formation between LNP bilayer containing the MC3 lipid, Lipid 2 or Lipid 10, and a plasma or endosomal bilayer. A) Currently accepted mode of action for LNP delivery. Once the LNP is in the bloodstream a protein corona is formed around the particle enabling endocytosis (not shown in the schematic representation for clarity), resulting in the LNP being encapsulated into the endosome within the cell. The endosome matures resulting in a pH drop from around 7 to 6-5. Upon the pH change the ionizable lipids become protonated, enabling interaction with the negatively charged lipids in the endosome. B) Representative frames of Martini simulation system of the flat LNP and plasma/endosomal membranes, the transition state, and the stalk (from left to right, respectively). The LNP model membrane is shown in orange while the target plasma membrane is shown in yellow. C) Comparison of stalk formation PMFs between LNPs bilayers containing MC3 lipid, Lipid 2 or Lipid 10, and the plasma membrane or the endosomal membrane models. The error is shown as shading in the same color as the corresponding line.

325 These fusion assays were conducted between a membrane mimicking the LNP formulations
326 and a simplified plasma membrane, with negatively charged lipids predominantly present in the
327 inner leaflet. However, considering the possibility that in the endosome, negatively charged lipids
328 might migrate to the LNP-interacting leaflet, we sought to evaluate the impact of this potential
329 redistribution. To this end, we performed additional PMF fusion assays against a membrane
330 model enriched with 10 mol % PAPS lipids in the LNP-interacting leaflet to better mimic the
331 compositional differences observed in the endosome. PS was used as the negative lipid for
332 simplicity and comparison to an earlier similar study [23].

333 The results for these fusion assays demonstrated a slight reduction in both the initial energetic
334 barrier for stalk formation and in the actual stalk across all three lipids (Figure 3C), though for
335 Lipid 10 most of the PMF curves overlap the difference in free energy for the stalk formation
336 at $x=1$ show a statistically meaningful difference, confirming the trend. This reduction in the
337 barrier reinforces the idea that anionic lipids, such as PS, may play an important role in the
338 endosomal membrane during the transfection mechanism. Moreover, the overall findings align with
339 experimental data indicating that LNPs containing Lipid 10 lead to higher protein expression [36],
340 thereby enhancing transfection efficiency.

341 2.3.2. Sterol-dependent fusion efficacy

342 In two other significant studies [42, 43], the influence of sterols on transfection has also been
343 emphasized. Various naturally occurring cholesterol analogs (phytosterols) have been shown to
344 markedly enhance transfection efficiency for different ILs, including the widely recognized MC3
345 lipid. To test this, we conducted additional PMF fusion assays using LNP bilayers containing
346 MC3:STEROL:DSPC (50:40:10 mol%), incorporating cholesterol, β -sitosterol, ergosterol, and
347 stigmasterol to the LNP bilayer. These were tested against the plasma membrane model [54], as
348 mentioned previously.

349 The resulting fusion PMFs show a more stable stalk formation with β -sitosterol, ergosterol, or
350 stigmasterol compared to cholesterol (Figure 4). This finding correlates with the increased order
351 observed for MC3 with double unsaturated tails (DU) and suggests a potential mechanism by
352 which substituting cholesterol with phytosterols in LNPs enhances fusion efficacy.




Fig. 4. Potential of mean force calculations of stalk formation with LNP membranes containing different sterols. PMFs of stalk formation between a plasma membrane model [54] and an LNP membrane containing MC3:DSPC:STEROL, with three different sterols.

353 2.4. Building LNPs at Coarse-Grained Resolution

354 Currently, the understanding of LNP structure and organization is limited, primarily based on
355 experimental techniques such as Small-Angle X-ray, Neutron Scattering (SAXS, SANS) and
356 low-resolution Cryo-Transmission Electron Microscopy data [5, 14]. While these methods provide
357 valuable insights, they often lack the resolution needed to fully elucidate the complex architecture
358 of LNPs. Simulation studies attempting to model and further understand LNP organization have
359 also been limited [15, 16, 19, 22, 23]. These studies typically focus on smaller bilayer patches or
360 particles, examining how pH variations affect lipid packing and distribution. Notably, only one
361 successful study has simulated the transfection of DNA cargo from a lipoplex [23].

362 Despite these efforts, our understanding of LNP structure remains incomplete, with various
363 factors such as cargo type, lipid formulation, manufacturing technique, pH, and buffer com-
364 position still needing comprehensive exploration [5, 14, 18, 52, 61, 62]. Proposed models for
365 LNP organization range widely—from multilamellar structures and nanostructured cores to
366 homogeneous core-shells, worm-like models, inverse hexagonal phases, bicontinuous cubic
367 phases, and even "bleb" compartments for LNPs containing mRNA [5, 14, 18, 52, 61, 62]. Among
368 these, the inverse hexagonal model is frequently mentioned for smaller cargoes such as siRNA
369 or polyA RNA, while the 'bleb' compartment model is often proposed for LNPs carrying
370 mRNA [5, 52].

371 Understanding these structures in greater detail is crucial for advancing the field, particularly
372 in the context of improving LNP efficacy and stability. To address these challenges, we now
373 turn our attention to the protocols and tools available for building coarse-grained LNP models,
374 followed by a case study analyzing the structure of an LNP composed of Lipid 2, Lipid 10, and
375 MC3.

376 2.4.1. Protocols and Tools for Building Coarse-Grained LNPs

377 To enable further studies of whole particles, we developed a protocol for constructing LNP
378 models. As an initial test case, we used an inverse hexagonal core at low pH, as observed
379 experimentally [5, 14]. This example demonstrates the protocol's capability to handle various
380 LNP structures.

381 When constructing an LNP, several considerations must be taken into account. LNPs are
382 potentially metastable structures that can significantly depend on the assembly process. In
383 this context, an integrative modeling approach—where LNPs are prebuilt based on available
384 experimental evidence and computational predictions—can be a valuable strategy for achieving
385 accurate representations of these complex particles.

386 In this work, we built a protocol to generate LNPs with the following parameters: a core
387 hydration level of approximately 12 water molecules per lipid, and a predefined lipid species
388 distribution with a total IL:DSPC:CHOL (for cholesterol) ratio of about 50:10:40 mol%. The
389 protocol constructs a low pH LNP with an inverse hexagonal core, encapsulated 7 strands of
390 RNA with water and neutralizing ions, and a coating consisting of a monolayer along the core
391 channels and a bilayer at the channel ends, closing off the channels. The core comprises IL and
392 cholesterol in a 3:1 ratio, while the coating is made of the remaining IL, cholesterol, and DSPC.
393 These considerations are based on experimental data for an MC3 LNP [5, 14].

394 The protocol allows for scaling the size of the cargo and the LNP and also adapt the core
395 to other LNP structures and shapes. Factors such as the protonation level of the ILs, the N/P
396 (nitrogen to phosphate) ratio, core hydration level, and ion concentration can be customized
397 by the user, guided by existing experimental data. Additionally, PEGylated lipids can be
398 incorporated into the LNP coating as observed experimentally [14]. The protocol utilizes several
399 tools, including TS2CG [63], Polyply [46], Packmol [64], Blender [65], MDVWhole [66],
400 MDVContainment [67], the Insane script [49], and VMD [68], combined into four steps (detailed
401 in the Methods section). Figure 5 provides an overview of the four main steps involved in the

402 building protocol, along with two test cases demonstrating different possible organizations for
 403 larger particles. The protocol and scripts are available on GitHub (<https://github.com/Martini-Force-Field-Initiative/M3-Ionizable-Lipids/>). Since the protocol is based on highly versatile
 404 tools such as TS2CG [63] and Polyply [46], it can be used as a starting point for constructing
 405 other LNP structures, such as the 'bleb' compartment LNP see in 5.
 406




Fig. 5. Representation of the building protocol for LNPs starting at low pH. Step 1) Build and simulate a periodic H_{II} phase with possible cargo and the desired water and ion content. Step 2) Extract the core by multiplying the periodic H_{II} phase in x, y, and z, depending on the desired size. Use VMD to generate a triangulated surface of the core. Step 3) Coat the core using TS2CG with the triangulated surface. A bilayer is placed on top of the otherwise open channels, and a monolayer along the sides of the channels. Step 4) If desired, PEGylated lipids can be added to the surface of the LNP using the PolyPly tool. Two test cases are shown below: one with an inverse hexagonal core and the other phase-separated into two compartments—a 'bleb' compartment containing water, ions, and cargo, and a compartment containing neutral ionizable lipids and cholesterol.

407 2.4.2. Case study: Analysis of LNP structure composed of Lipid 2, Lipid 10, and MC3

408 The protocol described previously was used to construct three LNPs with IL:DSPC:CHOL
 409 in a 50:10:40 ratio, incorporating the three ILs tested in the PMF fusion assays: MC3, Lipid
 410 2, and Lipid 10. PEGylated lipids were excluded, as they typically constitute only 1–2% of
 411 LNP formulations and because these particles were later used to study interactions with an

412 endosomal membrane model. In all three LNPs, the ILs were protonated. Seven RNA strands,
 413 comprising AU duplexes in a helical conformation, were used as cargo and encapsulated in an
 414 inverse hexagonal phase. During the 10 μ s simulations, all LNPs maintained a compact structure
 415 (Figure 6), preserving the encapsulated RNA and a generally spherical shape with an approximate
 416 diameter of \sim 20 nm. However, noticeable variations in internal morphology were observed when
 417 comparing LNPs formulated with Lipid 10 and MC3 to those formulated with Lipid 2.




Fig. 6. Structure of LNP models, all containing 7 strands of cargo: (A) Cross-section of LNP structures after 10 μ s of simulations at 310 K. Note, because it's a cross-section not all RNA strands are visible, however all are present within the water compartments in the LNP. Water inside LNPs is shown in cyan balls, RNA in yellow, CHOL in magenta, DSPC in violet, Lipid 10 in blue, Lipid 2 in green and MC3 in orange. (B) Time evolution of LNP hydration. (C) Radial number density profile of Lipid 10 containing LNP resulting from pre-built and self-assembly simulations. Water density is scaled by the factor of 0.1 to fit into plot.

418 While Lipid 10 and MC3 maintained an inverse hexagonal phase, Lipid 2 formed a multicompartmental vesicle with lipids preferring a lamellar organization (Figure 6). Intermolecular radial distribution function (RDF) between RNA surfaces of MC3 LNP did not evolve significantly during the simulation, with two peaks, at 4.7 and 9.3 nm (Figure S28). Lipid 10 was less organized, with RDF peaks at 4.3, 8.4 and 10.7 nm. Visually, both these LNPs preserved the inverse hexagonal phase for at least part of the LNP, in agreement with experimental observation of MC3 [5, 14]. On the other hand, Lipid 2 reshaped its internal organization, formed multicompartmental vesicle with RNA located on the water/lipid interface (Figure 6 Panel A), seemingly similar to the reported 'bleb' compartments observed with Cryo-EM pictures [52].

427 To investigate the impact of equilibration process, we performed additional simulated annealing of the LNPs. In all of the cases, final LNPs were less regular and more hydrated, see Figure 6B. 428 At 310 K, the LNPs in inverse hexagonal phase (Lipid 10 and MC3) contained \sim 12 mass% of water (Table S1) while Lipid 2-based LNP consisted \sim 16 % of water (Figure 6). Heating and cooling the systems led to LNPs with \sim 14 % of water in inverse hexagonal phase and 24 % in 430 431

432 case of multicompartamental vesicle of Lipid 2. The original ~690 Cl⁻ beads stayed mostly inside
433 the LNP, without significant differences between the systems (Table S1).

434 To further assess the robustness of the prebuilt structures, we conducted self-assembly
435 simulations using the same lipid compositions as in the pre-equilibrated structures. Within the
436 first tens of nanoseconds, lipids assembled around the RNA duplexes. In all of the systems
437 (including Lipid 2), lipids adopted an inverse hexagonal phase. As expected from an initial
438 random distribution of lipids, DSPC was not present only on the LNP surface, but equally
439 distributed in its interior (Figure 6C). Furthermore, LNPs were less hydrated (9–10 mass% of
440 water inside LNP, Table S1) and with a significant reduction of the amount of Cl⁻ beads trapped
441 within the core of LNP: 112 Cl⁻ for Lipid 10, 49 Cl⁻ for Lipid 2 and 128 Cl⁻ for MC3.

442 The findings suggest that the building protocol is reasonable, with MC3 LNP serving as
443 a control due to its known formation of an inverse hexagonal phase with polyA RNA at pH
444 6–4.5 [5, 14]. For Lipid 10 and 2 there is no experimental data on their organization at low pH,
445 however, we do observe Lipid 2 adapting a completely different organization rather quickly. This
446 shows, that even though we pre-built with an inverse hexagonal phase, other organizations can
447 easily be observed and that the LNP, at least in this case, is not stuck in the inverse hexagonal
448 phase.

449 Self-assembly simulations demonstrate that, for these smaller particles, ILs can rapidly organize
450 around RNA cargo to form structures similar to inverse hexagonal phases. However, a potential
451 limitation is the discrepancy in ion and hydration levels between prebuilt and self-assembly
452 simulations (Table S1). Additionally, the self-assembly simulations did not achieve a neutral core
453 in terms of neutralizing ions, likely due to the limitations of the reaction-field method used for
454 electrostatics. Ion translocation through the LNP can also be a slow process. Water molecules in
455 the core equilibrate relatively quickly (Figure S29), whereas ions require a longer time to reach
456 equilibrium, highlighting the importance of considering ion dynamics in the initial structure.
457 Overall, the protocol provides a viable approach for prebuilding LNPs with experimentally guided
458 parameters, offering a foundation for further studies and refinements.

459 2.4.3. Unbiased simulations of LNP-membrane fusion

460 Besides demonstrating the capabilities of the models for the three LNPs, we also inserted the
461 LNPs into a lipid vesicle representing the same membranes studied in the PMF fusion assays of
462 Section 2.3. Two different membrane models were used: one plasma membrane model without
463 charged lipids in the interacting leaflet, and another, called endosomal membrane model, with 10
464 mol% of PAPS lipids replaced by negatively charged PAPS.

465 During our simulations with LNPs embedded in lipid vesicles lacking negatively charged
466 lipid species in the interacting leaflet, no fusion phenomenon was observed. For each LNP, we
467 extended one of the simulations to over 20 μ s, simulating more than 120 μ s in total (Table S2).
468 Consistent with the high energy barrier observed in the PMF fusion assays, no LNP-vesicle
469 fusion occurred. This result also aligns with the kinetic barrier described by Leikin et al. [69],
470 which suggests that dehydration of the contact region or another initiation mechanism is required
471 for fusion to occur.

472 Incorporating negatively charged lipids into the interacting leaflet of the lipid vesicle may
473 accelerate the initiation of fusion between positively charged LNPs and the endosomal membrane
474 [55, 56]. To test this hypothesis, we modified the vesicles to contain 10 mol% of negatively
475 charged PAPS in the inner leaflet and performed three 10 μ s LNP-vesicle simulations for Lipid
476 10, Lipid 2, and MC3. For each IL system, LNP-vesicle fusion was observed in one replica
477 (Figure 7), while in the other three replicas, the LNP remained inside the vesicle without any
478 vesicle-LNP contacts. Although the unbiased approach did not clearly distinguish between the
479 three IL types, it confirmed that LNP and vesicle lipid fusion is not a barrierless process, even
480 with a fraction of negatively charged lipid in the vesicle. However, this barrier is reduced when

481 negatively charged lipids are present in the target membrane.

482 The unbiased simulations offer insights into the initial stages of the RNA transfection, in
483 particular the fusion of LNP and endosomal membrane. The LNP diffuses inside the vesicle
484 and approaches the vesicle membrane, separated by a thin layer of water (Figure 7A). The lipid
485 surfaces come close enough that individual lipids can interact. Negatively charged PAPS interacts
486 with the positively charged IL, and one of them is pulled out of the lipid layer, lying with its tail
487 on the lipid surface (lipid handshake, Figure 7B). If the lipid adopts an extended conformation
488 and embeds its other tail into the lipid vesicle (in the case of IL) or LNP (in the case of PAPS),
489 fusion begins (Figure 7C). Once the two lipid compartments are connected by this single lipid,
490 fusion is initiated and progresses rapidly (Figure 7,D).




Fig. 7. Left: Cross-section of the initial structure of MC3-LNP embedded in a lipid vesicle (left) and a detailed insight into the initiation of the LNP-vesicle fusion (A–D). The initial fused MC3 is shown in red. Right: Cross-section of fused structures after 7 μ s (Lipid 10) and 10 μ s (Lipid 2, MC3) of simulations with vesicle CHOL in cyan, other vesicle lipids in grey, RNA in yellow, LNP CHOL in pink, DSPC in purple, Lipid 10 in blue, Lipid 2 in green and MC3 in orange. Water and ions are omitted for clarity.

491 LNP fusion with the lipid vesicle induces deformation of the vesicle and mixing of LNP and
492 vesicle lipids. Initially, the intact lipid vesicle maintained a spherical shape, but the fusion process
493 disrupted this geometry, leading to elongations and other deformations of the vesicle (Figure
494 7). Cholesterol from both the LNP and vesicle intermingled and became evenly distributed
495 throughout the final structure. DSPC diffused into the inner leaflet of the vesicle, while a small
496 fraction of ILs flipped to the outer leaflet. However, the majority of ILs remained in contact
497 with RNA (Figure 7). In the final configuration, the RNA was predominantly surrounded by
498 cholesterol (originating from both the vesicle and the LNP) and some residual DSPC. Notably,
499 very few other vesicle lipids, apart from cholesterol, interacted with RNA by the end of the
500 simulation. The RNA-rich compartment was encased in a lipid monolayer primarily composed

501 of vesicle lipids (Figure 7). Although the induced deformations and RNA-lipid clustering might
502 impact the stability of the resulting particle, we did not observe any RNA translocation outside
503 the vesicle. This phenomenon has been reported for dsDNA in lipoplexes [23], but for RNA in
504 LNPs, it remains an open question.

505 While the ultimate goal of efficiently studying transfection remains a challenge, it lies beyond
506 the scope of this paper. Nevertheless, we have developed and presented the necessary models
507 and protocols to facilitate these studies in future research.

508 3. Discussions

509 Modeling LNPs and designing new formulations present unique challenges for physics-based
510 computational approaches due to several critical requirements. Firstly, achieving high chemical
511 specificity and accuracy in lipid interactions, while incorporating diverse system components –
512 such as solvents, ions, the target endosomal membrane lipids and LNP components, including
513 the encapsulated cargos like nucleic acids – can be demanding. Secondly, accurately simulating
514 the spatial and temporal scales necessary for LNP behavior and drug delivery poses significant
515 computational challenges. The complexity of these systems requires extensive computational
516 resources to model interactions over long timescales and large spatial domains. Additionally,
517 capturing the conformational flexibility of molecules and the precise thermodynamics of LNP
518 assembly and drug delivery is essential. Despite advances in *in silico* methods, many approaches
519 struggle to fully meet these demands, including coarse-grained (CG) methods.

520 Recent advancements in the Martini model, particularly Martini 3 [30], offer notable improve-
521 ments. The latest version features enhanced bead packing through optimized cross-interactions
522 between bead sizes, especially for charged groups, and re-parameterized bonded distances based
523 on molecular volume and shape. These upgrades result in more accurate representations of lipid
524 assemblies and improved packing of complex molecules. Furthermore, the expanded range of
525 chemical bead types in Martini 3 enhances coverage of the chemical space, making it especially
526 useful for modeling intricate LNP compositions used in vaccine delivery and gene therapy
527 applications. The model's application is increasingly shifting towards more complex biological
528 systems [26], including attempts to model entire cells [70]. In support of this direction, several
529 tools have been developed to aid these efforts [46, 63, 71, 72].

530 While our work highlights the significant advancements brought by Martini 3 and associated
531 tools such as TS2CG [63] and Polyply [46], it is important to acknowledge that these models and
532 approaches also have limitations and potential issues. One notable limitation is related to the
533 atomistic models used to parameterize bonded terms of lipids. Although lipid atomistic force
534 fields have undergone extensive benchmarking and evaluations over the years [73, 74], most efforts
535 have focused on standard biological phospholipids, particularly PC lipids. A careful evaluation
536 of models for ILs is still necessary. CHARMM36 [20, 37] with its extensive libraries provided
537 by CHARMM-GUI [75], is one of the most promising atomistic force fields for this purpose.
538 Another significant concern arises from the parametrization of non-bonded terms in Martini.
539 Given the lack of experimental data, the choice of bead chemical types in this work partially
540 relied on COSMO-RS [31] predictions. While COSMO-RS has demonstrated accuracy in logP
541 predictions [32, 33] and has been used effectively in other studies for Martini parametrization [76],
542 the adoption of this approach means that the Martini 3 lipid models developed here are based
543 on a fully bottom-up strategy. This kind of approach should still be considered with caution, as
544 it may not fully align with the Martini parametrization philosophy. This is one of the reasons
545 why consistency with experimentally determined bead assignments was also considered. Further
546 experimental validation of atomistic force fields and thermodynamic properties will be crucial
547 for future refinements of the Martini 3 IL models presented here.

548 Regardless of the quality of the Martini 3 LNP models, which will benefit from community
549 evaluation with their release, an important aspect of this work is the library of IL models.

550 Although this study parametrizes one of the most extensive sets of Martini lipids in the literature,
551 the library is still relatively small compared to the diversity of ILs explored in the literature. The
552 building-block approach using overlapping fragments is a promising idea that can expand the
553 library in the near future while maintaining consistency across different lipids. Automatic tools
554 for modeling small-molecule fragments and lipids, as Automartini [77], CGCompiler [78] and
555 Bartender [79], should further facilitate the expansion of lipid libraries. Further development of
556 AI-based tools could be particularly beneficial in this regard. Another more specific consideration
557 involves lipid tails. The Martini model has traditionally used a simplified approach, where the
558 same chain represents two tail lengths. For example, the classic DPPC lipid model represents
559 both di-C16:0 and di-C18:0 lengths. Given that Martini 3 can represent up to three resolutions
560 via beads of different sizes, current developments [80] may allow for more precise distinction of
561 tail lengths, which would significantly enhance the accuracy and expand the IL library models.

562 It is also important to note that the RNA Martini 3 models used in this work are still under
563 development. While these prototype models have shown reasonable results in stabilizing LNP
564 organization in the 'bleb' or inverted hexagonal assemblies (6A), they currently have limitations
565 in accurately representing RNA structure and possible conformational changes induced by
566 the lipid environment [81]. Further development of the RNA models could provide better
567 insights into how secondary structure and overall nucleobase content might influence LNP
568 assembly and transfection efficiency. Presently, optimization efforts for LNP lipid components
569 have been conducted separately from RNA sequence optimization. This separation, although
570 necessary due to current limitations, underscores the need for more integrated approaches that
571 can simultaneously account for both factors, ultimately leading to more effective LNP designs for
572 drug delivery applications.

573 Beyond the Martini models themselves, there are important considerations regarding the
574 protocols we suggest. The degree of protonation of ILs at different pH levels was not explored in
575 this work. We approximated IL lipids with pH 7 or higher as fully neutral and lower pH (5-6) as
576 fully protonated. Better consideration of the expected degree of protonation based on apparent
577 pKas, the influence of the environment (especially nucleic acid cargo), or the use of constant pH
578 approaches [82, 83] could improve the assignment of protonation states. Further development of
579 Martini constant pH approaches, such as the Titratable variant [84], would also be beneficial.

580 Another assumption, now made in building protocols and unbiased fusion assays, concerns
581 the variability of LNP morphologies, which are possibly metastable assemblies that can vary in
582 size and structure depending on the experimental process used in their production. Integrative
583 modeling approaches for prebuilding models seem ideal in this scenario, as precisely modeling
584 microfluidic experimental processes [3] used to synthesize LNPs is currently not feasible with
585 computational methods. However, the prebuild approach requires experimental information,
586 particularly some low-resolution data about the expected organization of the LNP core. Lack of
587 information on the concentration of water-soluble ions inside the internal water compartments
588 may be a concern in this approach. The self-assembly of small LNPs, as discussed in Section
589 2.4, highlights potential issues with ions. More experimental and theoretical studies should be
590 conducted to clarify the amount of ions and each LNP component in different subcompartments.
591 Further experimental validation of the standard Martini 3 model in reproducing LNP structures
592 would also be desirable, in particular concerning the electrostatic treatment used.

593 The PMF fusion assays described in Section 2.3 have proven extremely valuable for quantifying
594 the efficacy of stalk formation, the initial step in fusion, across different LNP formulations
595 and target membrane compositions. However, this approach has limitations: it is performed
596 in the absence of curvature in both the LNP and target membrane, and it does not account for
597 cargo. Additionally, the fusion protocol only quantifies stalk formation and does not encompass
598 other steps involved in complete transfection. While curvature may be incorporated by new
599 approaches [85] and additional collective variables could be applied to explore subsequent steps in

600 transfection, such as pore formation [86], PMF fusion assays rely on one fundamental assumption:
601 it assumes that the fusion process occurs in an equilibrium regime, where lipids of LNP and
602 endosomal membrane fully mix, which may not reflect the real endosomal escape process.
603 Unbiased fusion simulations presented in Section 2.4.3 provide a natural alternative to PMF
604 fusion assays, as they naturally account for curvature and cargo and reached similar conclusions
605 regarding the impact of negatively charged lipids on fusion. However, unbiased simulations
606 require significantly more sampling to distinguish between formulations and to fully capture
607 the transfection process [23], which remains challenging. Previous work has demonstrated that
608 observing the entire process is possible with unbiased simulations [23], although not observed in
609 our work. The lack of observed phenomena may be related to limitations in Martini, even in its
610 latest version, particularly in forming pores with potentially still show too larger barriers [87].

611 Finally, although our work has highlighted the importance of target endosomal models
612 in understanding transfection trends, larger benchmarks with more extensive sets of LNP
613 formulations are needed. Also comparing against *in vitro* experimental fusion trends, and not
614 only with *in vivo* protein expression [88], may help to isolate the impact of fusion from other
615 factors affecting RNA delivery efficiency, such as LNP structure and the interaction strength of
616 ILs with nucleic acids. Detailed lipidomics studies of endosomal membrane composition in
617 different cell types could also improve the accuracy of observed trends and aid in developing
618 cell-specific LNP formulations, which is a significant goal in the field, especially for promising
619 cancer vaccines [89,90].

620 **4. Conclusion**

621 We have developed and presented a comprehensive toolbox for *in silico* studies of Martini 3 LNPs,
622 offering a robust platform for advancing nucleic acid delivery systems. This toolbox includes an
623 extensive library of ionizable lipids and naturally occurring sterol models, specifically designed
624 for Martini 3, which can serve as essential building blocks in the study of LNPs. Additionally, we
625 provide a detailed protocol for constructing full-scale LNPs, guided by experimental data such as
626 cargo contents, PEGylation, lipid formulation, hydration levels, internal ion concentration, and
627 N/P ratio. Moreover, we have introduced a protocol for screening and quantifying the fusion
628 efficacy of various LNP formulations.

629 These models and protocols not only enable the detailed study of LNP organization, structure,
630 and fusion but also pave the way for routine screening of lipid mixtures, prediction of LNP
631 stability, and optimization of fusion efficacy. Through our showcase of Martini 3 LNP applications
632 in fusion assays, we have demonstrated the critical role of endosomal negatively charged lipids
633 in enhancing transfection efficiency and identified trends in fusion efficiency across different
634 LNP compositions. This underscores the importance of accurately modeling the endosomal
635 membrane to improve LNP predictions. Simulating whole LNPs with our toolkit can possibly
636 provide, in the future, additional insights into how lipid formulation influences corona formation
637 in the bloodstream, which is also a critical factor for LNP internalization into cells.

638 In summary, the toolbox we provide here empowers researchers to perform *in silico* optimization
639 of LNP compositions, potentially enhancing the efficacy of nucleic acid delivery, gene therapies,
640 and beyond. This work represents a significant step forward in the design and development of
641 more effective LNP-based delivery systems for a wide range of therapeutic applications.

642 **5. Data availability**

643 All the protocols, parameters, test systems, and plots for bonded distributions for each fragment
644 and lipid tested can be found on this GitHub page: <https://github.com/Martini-Force-Field-Initiative/M3-Ionizable-Lipids/>
645

646 **6. Methods**

647 All simulations were run using the GROMACS package versions 2019 and 2018 [91] and analyzed
648 using the python packages, MDAnalysis [92,93], Numpy [94], Scipy, scikit-learn, matplotlib [95],
649 Fatslim [96], MDVWhole [66], or GROMACS [91]. Visualization was performed using VMD,
650 Inkscape, or the Python RDkit package. [97–99] All CG simulations were modelled with the
651 Martini 3 CG model for biomolecular simulations [30]. For packing and constructing the
652 systems the packages Blender [65], insane [49], Packmol [64], TS2CG [63], PolyPly [46], and
653 MDVContainment [67] were used.

654 **6.1. Fragment modeling**

655 The design of the fragments was based on relevant ILs and divided into head and linker fragments.
656 The fragments were ensured to overlap with each other so that they could later be combined. The
657 mapping of the head or linker fragments was designed such that they were compatible with the
658 phospholipid tails and consistent across fragments, thereby ensuring the building block approach.
659 The bond distances were based on the center of geometry rule, with the mapping chosen to get
660 an optimal molecular volume and shape while keeping chemical groups within one bead, as
661 described in the parametrization guidelines of Martini 3 [30, 100] and tutorials [101].

662 **6.1.1. Atomistic modelling of fragments**

663 Once the fragments were identified and mapped, their atomistic parameters were obtained using
664 the software LigPargen [102], with the OPLS-AA/1.14*CM1A(-LBCC) force field [103]. Each
665 fragment was simulated for 1 μ s in water with 0.15 mM NaCl. For very hydrophobic linker
666 fragments, the fragment was simulated in bulk as well as in water.

667 Fragment systems were minimized using steepest descent with 5000 steps followed by a
668 relaxation of 250 ps using 1 fs timestep, and a production run of 1 μ s using 2 fs time step. The
669 temperature and pressure were held constant at 298 K and 1 bar using the Berendsen thermostat
670 and barostat [104] for relaxation and the V-rescale thermostat [105] and Parrinello-Rahman
671 barostat [106] for the production run.

672 The pressure coupling was isotropic with a compressibility of $4.5 \times 10^{-5} \text{ bar}^{-1}$. The
673 temperature was coupled using $\tau = 1 \text{ ps}$ during both relaxation and production run. For pressure
674 coupling, $\tau = 1 \text{ ps}$ was set during relaxation and 5 ps during the production. The electrostatics
675 were treated with the PME algorithm [107] using a cutoff of 1.2 nm, while the van der Waals
676 interactions were truncated, smoothly switching the force to zero between 1.0 and 1.2 nm [108].
677 Bonds involving hydrogen atoms were restricted using the LINCS algorithm [109].

678 **6.1.2. Parametrization of bonded terms**

679 Atomistic fragment simulations were mapped into coarse grained (CG) resolution using MD-
680 Analysis [92,93]. The bonded terms were then measured and the distributions plotted. The
681 fragment was then modeled in CG and simulated for 1 μ s in water with 0.15 mM NaCl. The
682 bonded distributions were fitted onto the corresponding atomistic distributions. For the highly
683 hydrophobic fragment, a bulk simulation was performed as well for 1 μ s.

684 For the CG fragment simulations, the system was minimized using 500 steps using the deepest
685 descent algorithm, followed by a relaxation of 10 ns, using 10 fs timestep, and final a 1 μ s
686 production run using 20 fs time step.

687 Temperature and pressure were kept constant during both the relaxation and production runs
688 at 310 K and 1 bar. The coupling for the pressure was isotropic, using the Berendsen [104]
689 and Parrinello-Rahman barostats [106] with $\tau = 12.0 \text{ ps}$ during respectively the relaxation and
690 production run, having the compressibility set to $3 \times 10^{-4} \text{ bar}^{-1}$. The Berendsen [104] and
691 Velocity-rescale thermostat [105] were used respectively for relaxation and production run with τ

692 = 1.0 ps for maintaining the temperature. The reaction field method was used to treat electrostatics
693 while van der Waals interactions were truncated after 1.1 nm (New-RF" Martini settings [110])
694 using the potential-shift Verlet scheme [108].

695 6.1.3. Reference partitioning free energies

696 Given the lack of experimental data, the reference partitioning free energies were estimated
697 using COSMO-RS approach [31]. Three partitioning systems were considered: octanol/water,
698 hexadecane/water and chloroform/water. For each molecule, 500 ps of semiempirical Born-
699 Oppenheimer molecular dynamics were performed at the GFN2-xtb [111] level, in gas phase,
700 with the xtb program [112]. Samples were taken from the resulting trajectory in such a way that
701 the spacing between samples corresponded to a value for the trajectory self-correlation function
702 less or equal to 0.05. Each sample was optimized at the BP86-D3(BJ)/def2-TZVP [113–116]
703 density-functional level of theory, and frequencies were obtained at the same level. Gibbs free
704 energies were obtained in gas-phase from those frequencies. The systems were then optimized
705 at the pre-defined BP-TZVP-COSMO level with a single-point calculation at the BP-TZVPD-
706 FINE-COSMO-SP level [31] for each sample. All the density-functional calculations used the RI
707 approximation [117] and were performed in Turbomole v7.7 [118]. From those calculations we
708 obtained the data required by COSMO-RS [31], as implemented in the COSMOtherm program.
709 Finally, the values obtained were averaged, weighted by their relative abundance in gas phase,
710 calculated from their Gibbs free energies, and the logarithm of the average was obtained. The
711 error bars correspond to the inter-quartile range for the non-weighted logP of all the employed
712 conformers.

713 6.1.4. Bead assignment, estimated CG partitioning free energies and SASA

714 Bead types and sizes were selected according to Martini 3 parametrization guidelines, ensuring
715 consistency with default bead assignments for specific chemical groups. These choices were
716 validated by estimating CG partitioning free energies. The calculated partitioning free energies
717 were obtained by Thermodynamic Integration [119]. The fragment was solvated in a $5 \times 5 \times 5$ nm²
718 box with either water or 25 % hydrated octanol [120, 121]. A set of 11 simulations were performed
719 with equally spaced points from 0 to 1, where fragment-solvent interactions were scaled down
720 from full ($\lambda = 0$) to zero ($\lambda = 1$). A stochastic integrator [122] was applied and each simulation
721 was minimized with 10,000 deep descent steps followed by a 50 ns production run. A soft-core
722 potential was applied with the parameters of $\alpha = 0.5$ and $p = 1$. The free energy was then
723 calculated using the Multistate Bennett Acceptance Ratio (MBAR) [123].

724 To ensure correct packing further validate the choices for bead sizes, the CG Solvent Accessible
725 Surface Area (SASA) was fitted against the atomistic mapped SASA as well, having less than
726 10% difference. The SASA was calculated using the GROMACS package [91] as described in
727 the Supporting Information of the Martini 3 paper [30].

728 6.2. Lipid modeling

729 Once the fragments were done, they were combined with known ILs from the literature and tested
730 against CHARMM36 [20, 37]. Bilayer simulations in both atomistic and CG resolution were
731 performed with a mixture of IL:POPC of 30:70 mol%.

732 6.2.1. CG bilayer simulations

733 Bilayer patches were constructed with a modified version of the insane software [49], which
734 is available in the GitHub repository associated with this work. The systems were neutralized
735 and ions added to obtain a 0.15 mM NaCl concentration using the GROMACS software [91].
736 The systems were simulated with the Martini 3 force field [30]. All systems were subjected
737 to the same relaxation protocol. First a minimization of 500 steps using steepest descent

738 followed by 10 ns of relaxation and finally 1–2 μ s production run. The target temperature was
739 310 K during both relaxation and production runs using, respectively, the Berendsen [104] and
740 Velocity-rescale thermostat [105] with $\tau = 1$ ps, coupling lipids separately from the solvent. The
741 pressure was maintained with a semiisotropic pressure coupling during relaxation and production
742 run using respectively the Berendsen [104] and Parrinello-Rahman [106] pressure coupled
743 with $\tau = 12$ ps and the compressibility at 3×10^{-4} bar⁻¹. The verlet buffer tolerance was set to
744 0.002 kJ mol⁻¹ ps⁻¹. The reaction field method was used to treat electrostatics and van der Waals
745 interactions were truncated after 1.1 nm ("New-RF" Martini settings [110]) using the potential
746 shift Verlet scheme [108].

747 6.2.2. Atomistic bilayer simulations

748 The atomistic bilayer patches were constructed using the CHARMM-GUI Membrane Builder
749 tool [75]. The CHARMM36 [20, 37] force field (FF) and the TIP3P water model were used, and
750 the systems were neutralized with 0.15 M NaCl. The systems were first minimized using the
751 steepest descent algorithm for 5000 steps, followed by 6 steps of relaxation, each 1 ns long with a
752 timestep of 1 fs, where position restraints on headgroups and dihedrals were gradually lowered
753 from 1000 to 0 kJ mol⁻¹nm⁻². For the production run, the timestep was increased to 2 fs.

754 For both the relaxation and production runs, the temperature and pressure were held constant at
755 310 K and 1 bar, respectively. The pressure was held constant using a semiisotropic coupling. In
756 the relaxation the Berendsen barostat and thermostat [104] was applied with $\tau = 1.0$ ps, while in
757 the production run the Velocity-rescale thermostat [105] with $\tau = 1.0$ ps and Parrinello-Rahman
758 barostat were used with $\tau = 5.0$ ps and a compressibility of 4.5×10^{-5} bar⁻¹. The lipids and
759 solvent were coupled independently.

760 Electrostatics were treated with the PME method [107] using a cutoff point of 1.2 nm while
761 van der Waals interactions were truncated, smoothly switching the force to zero between 1.0 and
762 1.2 nm. The bonds involving hydrogen atoms were constrained using the LINCS algorithm [109].

763 6.3. Sterol modelling

764 Sterol modelling followed the same parameterization strategies as those employed to model
765 cholesterol for Martini 3 [45]. Most sterol molecules parameterized in this work share their
766 sterol core with cholesterol, only differing on their aliphatic chains (β -sitosterol, stigmasterol and
767 campesterol). To model each of these a building block approach was used, where the cholesterol
768 sterol core was attached to the corresponding aliphatic chain. Aliphatic chain mapping and
769 bead typing followed standard Martini 3 parameterization guidelines [30]. Chain dynamics and
770 bonded parameters were modeled using reference CHARMM36 simulations of the corresponding
771 sterols [124], both inserted in POPC membranes and in water. To match atomistic reference
772 dynamics, 1 to 2 dihedral potentials and 2 to 4 angle potentials were employed. This is not unlike
773 the strategy used to model the Martini 3 cholesterol model [45], albeit complicated by the fact
774 that the sterols parameterized in this work have aliphatic chains made up of a larger number of
775 beads.

776 Ergosterol required us to model their sterol core. The same single-frame virtual site topology
777 approach that was used to model the cholesterol sterol core was applied to these molecules [45].
778 Additionally, the mapping was kept as close as possible to that used for cholesterol. In short,
779 three beads (typically R1, R2 and C1) were used to define a rigid triangular frame assembled
780 using linear constraints. The beads that make up this triangular frame were then used as the
781 constructing particles from which the remaining beads (other than aliphatic chain beads) were
782 defined as out-of-plane virtual sites. Parameters for virtual site construction were obtained
783 as described in detail elsewhere [45, 125, 126], from CHARMM36 simulations of each sterol
784 inserted in POPC bilayers. Briefly, the atomistic references were CG-mapped and the positions
785 of the particles were then averaged after rotationally and translationally fitting the entire molecule

786 to the virtual-site frame. The placement of the virtual site beads relative to the $frame_{ijk}$ was then
787 defined as a function of ij , ik and of their cross product. Nonbonded interactions between virtual
788 site particles were excluded. Martini bead masses were then redistributed from the virtual site
789 beads to the beads making up the virtual site frame. The corresponding aliphatic chains were
790 then attached to each core as described above.

791 Each sterol molecule was then validated to ensure correct behaviour and numerical stability.
792 For stability validation, large sterol containing bilayers $30 \times 30 \text{ nm}^2$ were simulated at 20 fs for
793 over 5 microseconds. For sterol behavior validation, $10 \times 10 \text{ nm}^2$ DPPC lipid bilayers containing
794 increasing concentrations of sterols were simulated at 323 K. Several membrane biophysical
795 properties were then probed, such as area per lipid, membrane thickness and acyl chain order.
796 Trends were compared between each sterol and against a cholesterol reference.

797 6.3.1. Bilayer melting temperature protocol

798 As part of the validation of the sterols, the melting temperature was calculated using a simulated
799 annealing approach, where the simulations starts at 373 K, followed by a quenching of the
800 temperature at a rate of 1 K/100 ns, until reaching 273 K, followed by a heating of 1 K/100 ns
801 returning to 373 K. The Lindemann index was then calculated for all lipid beads in blocks of
802 100 ns, such that each block corresponds to a change of approximately 1 K (Eq. 1, 2). Overheating
803 (T+) and under-cooling (T-) temperatures were determined using the largest gradient in the
804 Lindemann index. The mean T+ and T- were calculated from 5 repeats each of $2 \mu\text{s}$. The
805 simulation T_m was the obtained through Equation 3, known as the "hysteresis method" [127].

$$q_i = \frac{1}{(N-1)} \sum_{i \neq j} (\sqrt{\langle r_{ij}^2 \rangle} - \langle r_{ij} \rangle)^2 \quad (1)$$

$$Lindemann = \frac{1}{(N)} \sum_{i=1}^N (q_i) \quad (2)$$

$$T_m = T_+ + T_- - \sqrt{T_+ T_-} \quad (3)$$

806 The pressure, temperature, van der Waals and electrostatic interactions were treated as described
807 in section 5.2.1.

808 6.4. Nucleic acid models

809 A preliminary Martini 3 model for nucleic acids was used in this work for the simulations with
810 RNA. For simulations performed in LNP with an inverted hexagonal phase, 21 nucleotide-long
811 polyA dsRNA sequences were modeled using the same preliminary model employed in recent
812 biomolecular condensate studies [128, 129]. In this model, bead mapping and bonded parameters
813 were based on the phosphate and ribose of the Martini 2 nucleic acid models [130, 131], with
814 adaptations to the bead types. Phosphate groups are represented by Q5 beads, while ribose is
815 represented by SN3a-SP1 fragments. Aromatic nucleobase rings were already available with
816 Martini 3 [30]. Since this model was still a prototype, the π -stacking between nucleobases was
817 reinforced via an elastic networks. For the long 1,000 nucleotide polyA ssRNA used in the bleb
818 LNP, a more advanced, but still preliminary, model was utilized. This model did not include
819 elastic networks, with mapping and bonded terms aligned with Martini 3 guidelines. Specifically,
820 ribose fragments followed the recent guidelines suggested for carbohydrates [132]. Although
821 promising, this new prototype model presents some numerical instability, with all production
822 simulations performed using a 10 fs time step instead of the 20 fs time step used in the rest of
823 the CG simulations performed in this work. Coordinate and parameter files are provided on the
824 GitHub repository associated with this work.

825 6.5. LNP - Endosomal Bilayer Fusion assays

826 Bilayer fusion assays between LNP membranes with different ionizable lipids (MC3H, Lipid 2 or
827 Lipid 10) and a target plasma membrane were performed using the method described in [53].
828 We used a plasma membrane model called A8 [54], which has reduced complexity, but captures
829 reasonably well the properties of more complex compositions. The LNP interacting leaflet of
830 this membrane is composed of (in mol%) 24% POPC, 12% PAPC, 2% POPE, 6% DIPE, 24%
831 DPSM and 31% CHOL while the non-interacting leaflet contains 14% POPC, 8% PAPC, 5%
832 POPE, 16% DIPE, 11% DPSM, 28% CHOL, 25% PAPS, 2% PAP6. An additional membrane
833 model, enriched with 10 mol% PAPS lipids in the LNP-interacting leaflet, was also considered
834 to better model the differences in composition in the endosome. All bilayer fusion systems were
835 built with an automated protocol written in python, and the same protocol was used for all studies
836 of these systems, differing only in the composition of the membranes. Initially, two independent
837 membrane bilayers corresponding to the target LNP and endosomal target membrane are built
838 in a $10 \times 10 \times 8 \text{ nm}^3$ box using the insane software [49]. Each system was then hydrated and
839 neutralized using sodium ions. This was followed by energy minimization and equilibration for
840 20 ns to relax the box dimensions completely.

841 Subsequently, the two membranes were stacked on top of each other (as shown in Figure 4A).
842 To fully hydrate the distal leaflets, the box was extended along the z-axis, and additional water
843 was added to until there were 5 water beads per lipid between the proximal leaflets. Sodium
844 ions were introduced to neutralize the system's charge. The double membrane system was then
845 equilibrated for an additional 20 ns.

846 To avoid waters from permeating the leaflets and changing the hydration of the inner layer,
847 we applied flat-bottomed position restraints to all water beads. The reference positions of all
848 flat-bottomed position restraints were taken as the center of the box along z. The force constant
849 for the quadratic potential was set to $100 \text{ kJ mol}^{-1} \text{ nm}^{-2}$. Together, these flat-bottomed position
850 restraints potentials allowed normal diffusion and fluctuation of water in both compartments and
851 applied only if water beads deeply penetrated the hydrophobic membrane.

852 The initial frames for the umbrella sampling (US) simulations were extracted from constant-
853 velocity pulling simulations. In these simulations, the systems were pulled from reaction
854 coordinate $\xi_{\text{ch}} = 0.25$ to $\xi_{\text{ch}} = 1$ over 1000 ns using a force constant of 5000 kJ mol^{-1} , for five
855 replicates. Nineteen umbrella windows were employed, with reference positions ranging from
856 $\xi_{\text{ch}} = 0.1$ to 1 in increments of 0.05, where 1 is the fully formed stalk. The force constant was
857 set to 5000 kJ mol^{-1} . Each window was simulated for $1 \mu\text{s}$, with the initial 500 ns excluded for
858 equilibration. An integration time step of 20 fs was utilized. The potential of mean force (PMF)
859 was computed using the weighted histogram analysis method (WHAM) [133].

860 6.6. Constructing whole LNPs

861 6.6.1. Building protocol

862 The construction of whole LNPs with inverse hexagonal core utilizes the tool TS2CG [63],
863 Packmol [64], Polyply [46], the insane script [49], VMD [68] and the python packages fatslim [96],
864 MDAnalysis [92], MDVContainment [67], and MDVwhole [66]. The procedure is an evolution
865 of a protocol previously described for building cationic lipid/DNA lipoplex models studied in the
866 context of gene therapy delivery [23, 134]. The different steps for constructing the particles are
867 described in Jupyter notebooks and made available on the GitHub repository associated with this
868 work. Within the nookbooks are the parameters for construction set as well.

869 Step 1 involves constructing a periodic system of the inverse hexagonal phase of a given lipid
870 composition using TS2CG in combination with MDAnalysis and fatslim. A single cylinder is
871 constructed with TS2CG, with the principal axis aligned with the z-axis. The cylinder is then
872 filled with possible cargo, water and ions using Packmol. The cylinder is then replicated 3 times,

873 such that there is 4 cylinders in a hexagonal periodic box. This system is then relaxed for 10 ns.

874 Step 2 is the extraction of a hexagon from the periodic inverse hexagonal system. This
875 is done through duplicating the relaxed inverse hexagonal system using GROMACS, after
876 which MDVContainment along with MDVWhole are used to identify the different channels and
877 extracting a whole hexagon with 7 channels in total.

878 Step 3 is the coating of the core hexagonal system. VMD is used in combination with Blender
879 to obtain a triangulated surface of the hexagon, which is used as input for TS2CG to generate a
880 monolayer and a bilayer of the desired lipid composition for the coating of the hexagon. At the
881 top of the hexagon the channels are open, hence a bilayer is placed at either end of the channels
882 such that the hydrophilic headgroups of the lipids are facing both the open channels as well as the
883 solvent. Along the channels the monolayer is placed, with the lipid headgroups facing the solvent.

884 Step 4 involves possible PEGylation of the coating using Polyply, resulting in a LNP with 20
885 nm in diameter.

886 A similar procedure was performed to build a larger LNP with a diameter of approximately 40
887 nm. In this case, after step 1, the relaxed inverse hexagonal system was replicated in step 2 to
888 generate an LNP with 44 channels in total, followed by the same procedures described in steps 3
889 and 4. For the 'bleb' structure, steps 1 and 2 were replaced by the construction of two vesicle-like
890 compartments using TS2CG and Polyply. One compartment contained water, ions, and a long
891 1,000 ssRNA chain, while the other contained neutral ionizable lipids and cholesterol. After
892 construction, both compartments were relaxed and the outer coating was generated, as described
893 in Steps 3 and 4. After construction, the resulting LNP particles are then solvated and the desired
894 ions are added using insane and GROMACS, followed by 5 steps of relaxation, as detailed in the
895 Jupyter notebooks.

896 6.6.2. Assessment of the pre-build structures

897 The pre-built LNPs were equilibrated for 10 μ s at a) constant temperature of 310 K and b) via
898 rapid periodic simulated annealing with linear heating and cooling the system between 290 and
899 390 K in 40 ns cycles. The remaining simulation parameters were the same as in other production
900 simulations in this manuscript, except for the use of isotropic pressure coupling.

901 To also compare different strategies for generating LNP models, we performed also self-
902 assembly simulations of the same composition of lipids and RNA molecules as in the prebuilt
903 structures. The molecules were randomly inserted into a cubic simulation box (18 nm side).
904 The box was enlarged (35 nm side), hydrated, neutralized with Cl⁻ ions and then Cl⁻ and Na⁺
905 ions were added in physiological conditions. The system was equilibrated and simulated for
906 10 μ s with annealing, as in the case of pre-assembled LNPs and in previous work [15]. The
907 structures of the LNPs were then characterized in terms of their size, shape, density distribution
908 and hydration level using the same protocols provided in ref [15], with average values calculated
909 for the last 2 μ s of the simulation.

910 In order to evaluate the role of initial hydration and ionization level of the LNP, we modified the
911 structure of LNP with Lipid 2. We reduced the number of water beads up to a full dehydration of
912 the initial structure (90, 80, 50 and 0% of original water level). Further, we reduced the number
913 of Cl⁻ ions to 90, 50 and 0% of original level at the fully hydrated structure and to 50 and 0% at
914 the fully and 50 % dehydrated LNP structure (Figure S29). The LNPs were simulated for 10 μ s
915 with annealing as other LNPs in this paper and their level of their hydration was evaluated as in
916 ref [15].

917 Further, we tested the changing LNP morphology dependent on the protonation level of Lipid
918 2. We used the initial structure of fully protonated LNP with Lipid 2 and deprotonated a fraction
919 of Lipid 2 (Figure S30), keeping the system net-neutral (replacing the required amount of Cl⁻ ions
920 by water beads) and simulated them for 10 μ s with annealing. The protonation or deprotonation
921 of 10% of ILs did not make a significant difference in the LNP structure. Deprotonation of more

922 molecules of Lipid 2 resulted in RNA cluster surrounded by a bulk lipid phase (Figure S30).

923 6.7. Unbiased fusion simulations of whole LNPs

924 For unbiased fusion simulations we used the approach of simulating an LNP encapsulated in a
925 lipid vesicle. Three lipid vesicles with outer diameters ranging from 15–16 nm were prepared
926 by TS2CG tool [63] with water pores of 2 nm in diameter. The lipid composition of the lipid
927 vesicle corresponded to the plasma membrane model used in the fusion assays in section 2.3 with
928 negatively charged lipids (PAPS) in the outer non-interacting membrane leaflet. Lipid tails were
929 excluded from the region of water pore with cylindrical restraints and a short vacuum energy
930 minimization was performed (as recommended in the original vesicle formation protocol). The
931 equilibrated structure of the LNP was inserted inside the lipid vesicle to align the LNP and vesicle
932 centers of gyration. The LNP was restrained at its original position for the whole time of the
933 equilibration (with force constant of $1,000 \text{ kJ mol}^{-1} \text{ nm}^{-2}$). Afterwards, the system was solvated
934 and neutralized with Na^+ ions and minimized again. During system equilibration, neutral and
935 negatively charged vesicle lipids were treated differently. Neutral lipids were only restrained by
936 keeping their tails out of the water pore (with $1,000 \text{ kJ mol}^{-1} \text{ nm}^{-2}$), that was gradually closing
937 (with 2.0, 1.5, 1.0 nm in diameter). Charged lipids were kept out of the pore with higher force
938 (with $10,000 \text{ kJ mol}^{-1} \text{ nm}^{-2}$) and their headgroups were restrained spherically to stay in the outer
939 leaflet. This process did not prevent all flip-flops or vesicle deformations, therefore after pore
940 reduction to 1.0 nm in diameter, charged PAPS in the internal leaflet were changed to PAPC, and
941 PAP6 was removed. Further, lipids in vesicle deformations were removed. The equilibration
942 with 1.0 nm pore was repeated, followed by steps with 0.5 and 0.2 nm of pore diameter. Finally,
943 all restraints were removed and the LNP-vesicle system was simulated for at least $10 \mu\text{s}$ with
944 the same simulation protocol as bare LNPs at 310 K (see the Table S2). For each LNP, three
945 different vesicles were prepared and simulated independently.

946 To evaluate the role of negatively charged lipids in the fusion process, we prepared another
947 set of lipid vesicles with 10 % of lipids of the internal leaflet exchanged for PAPS, mimicking
948 the endosomal membrane. We used the same lipid vesicles as in the previous case (after the
949 equilibration), exchanged the required amount of PAPC with PAPS and performed $10 \mu\text{s}$ of
950 simulations.

951 7. Acknowledgments

952 The authors would like to thank Dr Ignacio Faustino, Linus Grünewald and Jan A. Stevens for
953 their contributions in the preliminary Martini 3 models of nucleic acids and their implementation
954 in Martinize2 and Polyply codes. P.C.T.S. also acknowledge Riccardo Pellarin and Carlos M.
955 Marques for the valuable discussions. L.R.K., L.B.A and P.C.T.S would like to thank the support
956 of the French National Center for Scientific Research (CNRS) and the funding from research
957 collaboration agreements with PharmCADD. This work was granted access to the HPC resources
958 of IDRIS, CINES and TGCC under the allocations 2022-A0120713456 and 2023-A0140713456
959 made by GENCI. M.V., L.B.A and P.C.T.S also acknowledge the support of the PSMN (Pôle
960 Scientifique de Modélisation Numérique) and the Centre Blaise Pascal's IT test platform at ENS
961 de Lyon (Lyon, France) for the computer facilities. The platform operates the SIDUS solution
962 developed by Emmanuel Quemener [135]. R.M-A. and R.A-O. thank ANID-Chile for support
963 under FONDECYT N. 1240992. S.J.M. acknowledges funding from the European Research
964 Council with the Advanced grant "COMP-O-CELL" (101053661). L.M. acknowledges funding
965 by the Institut National de la Santé et de la Recherche Médicale (INSERM). M.P., M.Š. and M.O.
966 acknowledge VSB-Technical University of Ostrava, IT4Innovations National Supercomputing
967 Center, Czech Republic for granting this project access to the LUMI supercomputer owned
968 by the EuroHPC Joint Undertaking, hosted by CSC (Finland) and the LUMI consortium with
969 the support of the Ministry of Education, Youth and Sports of the Czech Republic through

970 e-INFRA CZ (grant 90254). COST Action CA21101 is also acknowledged. The work was also
971 supported by the ERDF/ESF project TECHSCALE (No. CZ.02.01.02/00/22_008/0004578) and
972 by the European Union under the REFRESH - Research Excellence for Region Sustainability
973 and High-tech Industries project (No. CZ.10.03.01/00/22_003/0000048) via the Operational
974 Program Just Transition.

975 References

- 976 1. L. R. Kjolbye, G. P. Pereira, A. Bartocci, M. Pannuzzo, S. Albani, A. Marchetto, B. Jiménez-García, J. Martin,
977 G. Rossetti, M. Cecchini, S. Wu, L. Monticelli, and P. C. T. Souza, "Towards design of drugs and delivery systems
978 with the Martini coarse-grained model," *QRB Discov.* **3** (2022).
- 979 2. Y. Jia, X. Wang, L. Li, F. Li, J. Zhang, and X.-J. Liang, "Lipid nanoparticles optimized for targeting and release of
980 nucleic acid," *Adv. Mater.* **36**, 2305300 (2024).
- 981 3. M. Mehta, T. A. Bui, X. Yang, Y. Aksoy, E. M. Goldys, and W. Deng, "Lipid-based nanoparticles for drug/gene
982 delivery: An overview of the production techniques and difficulties encountered in their industrial development,"
983 *ACS Mater. Au* **3**, 600–619 (2023).
- 984 4. M. Cárdenas, R. A. Campbell, M. Yanez Arteta, M. J. Lawrence, and F. Sebastiani, "Review of structural design
985 guiding the development of lipid nanoparticles for nucleic acid delivery," *Curr. Opin. Colloid Interface Sci.* **66**
986 (2023).
- 987 5. J. Philipp, A. Dabkowska, A. Reiser, K. Frank, R. Krzysztóń, C. Brummer, B. Nickel, C. E. Blanchet, A. Sudarsan,
988 M. Ibrahim, S. Johansson, P. Skantze, U. Skantze, S. Östman, M. Johansson, N. Henderson, K. Elvevold, B. Smedsrød,
989 N. Schwierz, L. Lindfors, and J. O. Rädler, "pH-dependent structural transitions in cationic ionizable lipid mesophases
990 are critical for lipid nanoparticle function," *Proc. National Acad. Sci. United States Am.* **120**, e2310491120 (2023).
- 991 6. M. Schlich, R. Palomba, G. Costabile, S. Mizrahy, M. Pannuzzo, D. Peer, and P. Decuzzi, "Cytosolic delivery of
992 nucleic acids: The case of ionizable lipid nanoparticles," *Bioeng. Transl. Med.* **6** (2021).
- 993 7. L. Digiacomo, S. Renzi, E. Quagliarini, D. Pozzi, H. Amenitsch, G. Ferri, L. Pesce, V. De Lorenzi, G. Matteoli,
994 F. Cardarelli, and G. Caracciolo, "Investigating the mechanism of action of dna-loaded pegylated lipid nanoparticles,"
995 *Nanomedicine: Nanotechnology, Biol. Med.* **53**, 102697 (2023).
- 996 8. C. Hald Albertsen, J. A. Kulkarni, D. Witzigmann, M. Lind, K. Petersson, and J. B. Simonsen, "The role of lipid
997 components in lipid nanoparticles for vaccines and gene therapy," *Adv. Drug Deliv. Rev.* **188**, 114416 (2022).
- 998 9. W. Li and F. C. Szoka, "Lipid-based nanoparticles for nucleic acid delivery," *Pharm. Res.* **24**, 438–449 (2007).
- 999 10. S. H. Kiaie, N. Majidi Zolbanin, A. Ahmadi, R. Bagherifar, H. Valizadeh, F. Kashanchi, and R. Jafari, "Recent
1000 advances in mRNA-LNP therapeutics: immunological and pharmacological aspects," *J. Nanobiotechnology* **20**
1001 (2022).
- 1002 11. V. Agarwal and D. R. Kelley, "The genetic and biochemical determinants of mRNA degradation rates in mammals,"
1003 *Genome Biol.* **23** (2022).
- 1004 12. S. Moayedpour, J. Broadbent, S. Riahi, M. Bailey, H. V. Thu, D. Dobchev, A. Balsubramani, R. N.D. Santos, L. Kogler-
1005 Anele, A. Corrochano-Navarro, S. Li, F. U. Montoya, V. Agarwal, Z. Bar-Joseph, and S. Jager, "Representations of
1006 lipid nanoparticles using large language models for transfection efficiency prediction," *Bioinformatics* **40**, btac342
1007 (2024).
- 1008 13. S. Chatterjee, E. Kon, P. Sharma, and D. Peer, "Endosomal escape: A bottleneck for LNP-mediated therapeutics,"
1009 *Proc. National Acad. Sci. United States Am.* **121**, e2307800120 (2024).
- 1010 14. M. Y. Arteta, T. Kjellman, S. Bartesaghi, S. Wallin, X. Wu, A. J. Kvist, A. Dabkowska, N. Székely, A. Radulescu,
1011 J. Bergholtz, and L. Lindfors, "Successful reprogramming of cellular protein production through mRNA delivered
1012 by functionalized lipid nanoparticles," *Proc. National Acad. Sci. United States Am.* **115**, E3351–E3360 (2018).
- 1013 15. M. Paloncýová, M. Šrejber, P. Čechová, P. Kührová, F. Zaoral, and M. Otyepka, "Atomistic Insights into Organization
1014 of RNA-Loaded Lipid Nanoparticles," *J. Phys. Chem. B* **127**, 1158–1166 (2023).
- 1015 16. M. Paloncýová, P. Čechová, M. Šrejber, P. Kührová, and M. Otyepka, "Role of Ionizable Lipids in SARS-CoV-2
1016 Vaccines As Revealed by Molecular Dynamics Simulations: From Membrane Structure to Interaction with mRNA
1017 Fragments," *J. Phys. Chem. Lett.* **12**, 11199–11205 (2021).
- 1018 17. M. Ramezanpour and D. P. Tieleman, "Computational Insights into the Role of Cholesterol in Inverted Hexagonal
1019 Phase Stabilization and Endosomal Drug Release," *Langmuir* **38**, 7462–7471 (2022).
- 1020 18. J. A. Kulkarni, M. M. Darjuan, J. E. Mercer, S. Chen, R. Van Der Meel, J. L. Thewalt, Y. Y. C. Tam, and P. R. Cullis,
1021 "On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA," *ACS*
1022 *Nano* **12**, 4787–4795 (2018).
- 1023 19. M. F. Trollmann and R. A. Böckmann, "mRNA lipid nanoparticle phase transition," *Biophys. journal* **121**, 3927–3939
1024 (2022).
- 1025 20. S. Park, Y. K. Choi, S. Kim, J. Lee, and W. Im, "CHARMM-GUI Membrane Builder for Lipid Nanoparticles with
1026 Ionizable Cationic Lipids and PEGylated Lipids," *J. Chem. Inf. Model.* **61**, 5192–5202 (2021).
- 1027 21. M. Cornebise, E. Narayanan, Y. Xia, E. Acosta, L. Ci, H. Koch, J. Milton, S. Sabnis, T. Salerno, and K. E. Benenato,
1028 "Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions
1029 with mRNA," *Adv. Funct. Mater.* **32** (2022).

- 1030 22. A. K. Leung, I. M. Hafez, S. Baoukina, N. M. Belliveau, I. V. Zhigaltsev, E. Afshinmanesh, D. P. Tieleman, C. L.
1031 Hansen, M. J. Hope, and P. R. Cullis, "Lipid nanoparticles containing siRNA synthesized by microfluidic mixing
1032 exhibit an electron-dense nanostructured core," *J. Phys. Chem. C* **116**, 18440–18450 (2012).
- 1033 23. B. M. Bruininks, P. C. T. Souza, H. I. Ingólfsson, and S. J. Marrink, "A molecular view on the escape of lipoplex
1034 dna from the endosome," *eLife* **9** (2020).
- 1035 24. S. J. Marrink, H. J. Risselada, S. Yefimov, D. P. Tieleman, and A. H. de Vries, "The MARTINI force field: Coarse
1036 grained model for biomolecular simulations," *J. Phys. Chem. B* **111**, 7812–7824 (2007).
- 1037 25. S. J. Marrink, L. Monticelli, M. N. Melo, R. Alessandri, D. P. Tieleman, and P. C. T. Souza, "Two decades of martini:
1038 Better beads, broader scope," *WIREs Comput. Mol. Sci.* **13**, e1620 (2023).
- 1039 26. S. J. Marrink, V. Corradi, P. C. T. Souza, H. I. Ingólfsson, D. P. Tieleman, and M. S. Sansom, "Computational
1040 modeling of realistic cell membranes," *Chem. Rev.* **119**, 6184–6226 (2019). PMID: 30623647.
- 1041 27. R. Alessandri, F. Grünewald, and S. J. Marrink, "The martini model in materials science," *Adv. Mater.* **33**, 2008635
1042 (2021).
- 1043 28. N. Machado, B. M. Bruininks, P. Singh, L. Dos Santos, C. Dal Pizzol, G. d. C. Dieamant, O. Kruger, A. A. Martin,
1044 S. J. Marrink, P. C. Souza *et al.*, "Complex nanoemulsion for vitamin delivery: droplet organization and interaction
1045 with skin membranes," *Nanoscale* **14**, 506–514 (2022).
- 1046 29. Y. Cao, J. Zhu, J. Kou, D. P. Tieleman, and Q. Liang, "Unveiling interactions of tumor-targeting nanoparticles with
1047 lipid bilayers using a titratable martini model," *J. Chem. Theory Comput.* **20**, 4045–4053 (2024).
- 1048 30. P. C. T. Souza, R. Alessandri, J. Barnoud, S. Thallmair, I. Faustino, F. Grünewald, I. Patmanidis, H. Abdzadeh, B. M.
1049 Bruininks, T. A. Wassenaar, P. C. Kroon, J. Melcer, V. Nieto, V. Corradi, H. M. Khan, J. Domański, M. Javanainen,
1050 H. Martinez-Seara, N. Reuter, R. B. Best, I. Vattulainen, L. Monticelli, X. Periole, D. P. Tieleman, A. H. de Vries,
1051 and S. J. Marrink, "Martini 3: a general purpose force field for coarse-grained molecular dynamics," *Nat. Methods*
1052 **2021** 18:4 **18**, 382–388 (2021).
- 1053 31. A. Klamt, "The cosmo and cosmo-rs solvation models," *WIREs Comput. Mol. Sci.* **1**, 699–709 (2011).
- 1054 32. M. Işık, T. D. Bergazin, T. Fox, A. Rizzi, J. D. Chodera, and D. L. Mobley, "Assessing the accuracy of octanol–water
1055 partition coefficient predictions in the sampl6 part ii log p challenge," *J. Comput. Mol. Des.* **34**, 335–370 (2020).
- 1056 33. T. D. Bergazin, N. Tielker, Y. Zhang, J. Mao, M. R. Gunner, K. Francisco, C. Ballatore, S. M. Kast, and D. L. Mobley,
1057 "Evaluation of log P, pK_a, and log D predictions from the SAMPL7 blind challenge," *J. Comput. Mol. Des.* **35**,
1058 771–802 (2021).
- 1059 34. J. Sangster, "Octanol-Water Partition Coefficients of Simple Organic Compounds," *J. Phys. Chem. Ref. Data* **18**,
1060 1111–1229 (1989).
- 1061 35. K. J. Hassett, K. E. Benenato, E. Jacquinet, A. Lee, A. Woods, O. Yuzhakov, S. Himansu, J. Deterling, B. M. Geilich,
1062 T. Ketova, C. Mihai, A. Lynn, I. McFadyen, M. J. Moore, J. J. Senn, M. G. Stanton, Almarsson, G. Ciaramella,
1063 and L. A. Brito, "Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines," *Mol.*
1064 *therapy. Nucleic acids* **15**, 1–11 (2019).
- 1065 36. S. Sabnis, E. S. Kumarasinghe, T. Salerno, C. Mihai, T. Ketova, J. J. Senn, A. Lynn, A. Bulychev, I. McFadyen,
1066 J. Chan, Almarsson, M. G. Stanton, and K. E. Benenato, "A Novel Amino Lipid Series for mRNA Delivery: Improved
1067 Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates," *Mol. therapy : journal Am.*
1068 *Soc. Gene Ther.* **26**, 1509–1519 (2018).
- 1069 37. J. B. Klauda, R. M. Venable, J. A. Freites, J. W. O'Connor, D. J. Tobias, C. Mondragon-Ramirez, I. Vorobyov, A. D. J.
1070 MacKerell, and R. W. Pastor, "Update of the charmm all-atom additive force field for lipids: Validation on six lipid
1071 types," *The J. Phys. Chem. B* **114**, 7830–7843 (2010). PMID: 20496934.
- 1072 38. S. C. Semple, A. Akinc, J. Chen, A. P. Sandhu, B. L. Mui, C. K. Cho, D. W. Sah, D. Stebbing, E. J. Crosley,
1073 E. Yaworski, I. M. Hafez, J. R. Dorkin, J. Qin, K. Lam, K. G. Rajeev, K. F. Wong, L. B. Jeffs, L. Nechev, M. L.
1074 Eisenhardt, M. Jayaraman, M. Kazem, M. A. Maier, M. Srinivasulu, M. J. Weinstein, Q. Chen, R. Alvarez, S. A.
1075 Barros, S. De, S. K. Klimuk, T. Borland, V. Kosovrasti, W. L. Cantley, Y. K. Tam, M. Manoharan, M. A. Ciufolini,
1076 M. A. Tracy, A. De Fougères, I. MacLachlan, P. R. Cullis, T. D. Madden, and M. J. Hope, "Rational design of
1077 cationic lipids for siRNA delivery," *Nat. Biotechnol.* **28**, 172–176 (2010).
- 1078 39. M. J. Carrasco, S. Alishetty, M. G. Alameh, H. Said, L. Wright, M. Paige, O. Soliman, D. Weissman, T. E. Cleveland,
1079 A. Grishaev, and M. D. Buschmann, "Ionization and structural properties of mRNA lipid nanoparticles influence
1080 expression in intramuscular and intravascular administration," *Commun. Biol.* **2021** 4:1 **4**, 1–15 (2021).
- 1081 40. F. Ding, H. Zhang, J. Cui, Q. Li, and C. Yang, "Boosting ionizable lipid nanoparticle-mediated in vivo mRNA
1082 delivery through optimization of lipid amine-head groups," *Biomater. Sci.* **9**, 7534–7546 (2021).
- 1083 41. X. Cheng and R. J. Lee, "The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery,"
1084 *Adv. drug delivery reviews* **99**, 129–137 (2016).
- 1085 42. S. Patel, N. Ashwanikumar, E. Robinson, Y. Xia, C. Mihai, J. P. Griffith, S. Hou, A. A. Esposito, T. Ketova, K. Welscher,
1086 J. L. Joyal, Almarsson, and G. Sahay, "Naturally-occurring cholesterol analogues in lipid nanoparticles induce
1087 polymorphic shape and enhance intracellular delivery of mRNA," *Nat. Commun.* **2020** 11:1 **11**, 1–13 (2020).
- 1088 43. Y. Eygeris, S. Patel, A. Jozic, G. Sahay, and G. Sahay, "Deconvoluting Lipid Nanoparticle Structure for Messenger
1089 RNA Delivery," *Nano Lett.* **20**, 4543–4549 (2020).
- 1090 44. J. Zhang, H. Fan, D. A. Levorse, and L. S. Crocker, "Interaction of cholesterol-conjugated ionizable amino lipids
1091 with biomembranes: Lipid polymorphism, structure-activity relationship, and implications for siRNA delivery,"
1092 *Langmuir* **27**, 9473–9483 (2011).

- 1093 45. L. Borges-Araújo, A. C. Borges-Araújo, T. N. Ozturk, D. P. Ramirez-Echemendia, B. Fábíán, T. S. Carpenter,
1094 S. Thallmair, J. Barnoud, H. I. Ingólfsson, G. Hummer, D. P. Tieleman, S. J. Marrink, P. C. T. Souza, and M. N.
1095 Melo, “Martini 3 coarse-grained force field for cholesterol,” *J. Chem. Theory Comput.* **19**, 7387–7404 (2023).
- 1096 46. F. Grünewald, R. Alessandri, P. C. Kroon, L. Monticelli, P. C. T. Souza, and S. J. Marrink, “Polyply: a python suite
1097 for facilitating simulations of macromolecules and nanomaterials,” *Nat. Commun.* 2022 13:1 **13**, 1–12 (2022).
- 1098 47. F. Grünewald, “Material design using martini: Accelerating discovery through coarse-grained simulations,” Ph.D.
1099 thesis, University of Groningen (2023).
- 1100 48. M. Ibrahim, J. Gilbert, M. Heinz, T. Nylander, and N. Schwierz, “Structural insights on ionizable Dlin-MC3-DMA
1101 lipids in DOPC layers by combining accurate atomistic force fields, molecular dynamics simulations and neutron
1102 reflectivity,” *Nanoscale* **15**, 11647–11656 (2023).
- 1103 49. T. A. Wassenaar, H. I. Ingólfsson, R. A. Böckmann, D. P. Tieleman, and S. J. Marrink, “Computational lipidomics
1104 with insane: A versatile tool for generating custom membranes for molecular simulations,” *J. Chem. Theory Comput.*
1105 **11**, 2144–2155 (2015).
- 1106 50. K. Hashiba, Y. Sato, M. Taguchi, S. Sakamoto, A. Otsu, Y. Maeda, T. Shishido, M. Murakawa, A. Okazaki, and
1107 H. Harashima, “Branching Ionizable Lipids Can Enhance the Stability, Fusogenicity, and Functional Delivery of
1108 mRNA,” *Small Sci.* **3**, 2200071 (2023).
- 1109 51. Y. Li, Z. Ye, H. Yang, and Q. Xu, “Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic
1110 acids, proteins, and drugs,” *Acta Pharm. Sinica B* **12**, 2624–2639 (2022).
- 1111 52. M. L. Brader, S. J. Williams, J. M. Banks, W. H. Hui, Z. H. Zhou, and L. Jin, “Encapsulation state of messenger RNA
1112 inside lipid nanoparticles,” *Biophys. J.* **120**, 2766–2770 (2021).
- 1113 53. C. S. Poojari, K. C. Scherer, and J. S. Hub, “Free energies of membrane stalk formation from a lipidomics perspective,”
1114 *Nat. Commun.* 2021 12:1 **12**, 1–10 (2021).
- 1115 54. H. I. Ingólfsson, H. Bhatia, T. Zeppelin, W. F. Bennett, K. A. Carpenter, P. C. Hsu, G. Dharuman, P. T. Bremer,
1116 B. Schiøtt, F. C. Lightstone, and T. S. Carpenter, “Capturing Biologically Complex Tissue-Specific Membranes at
1117 Different Levels of Compositional Complexity,” *J. Phys. Chem. B* **124**, 7819–7829 (2020).
- 1118 55. Y. S. Tarahovsky, R. Koynova, and R. C. MacDonald, “Dna release from lipoplexes by anionic lipids: Correlation
1119 with lipid mesomorphism, interfacial curvature, and membrane fusion,” *Biophys. J.* **87**, 1054–1064 (2004).
- 1120 56. T. Kobayashi, M.-H. Beuchat, J. Chevallier, A. Makino, N. Mayran, J.-M. Escola, C. Lebrand, P. Cosson, T. Kobayashi,
1121 and J. Gruenberg, “Separation and characterization of late endosomal membrane domains,” *J. biological chemistry*
1122 **277**, 32157–32164 (2002).
- 1123 57. V. S. Markin, M. M. Kozlov, and V. L. Borovjagin, “On the theory of membrane fusion. The stalk mechanism.” *Gen.*
1124 *Physiol. Biophys.* **3**, 361–377 (1984).
- 1125 58. L. V. Chernomordik and M. M. Kozlov, “Mechanics of membrane fusion,” *Nat. structural & molecular biology* **15**,
1126 675–683 (2008).
- 1127 59. Y. Yan, X. Liu, L. Wang, C. Wu, Q. Shuai, Y. Zhang, and S. Liu, “Branched hydrophobic tails in lipid nanoparticles
1128 enhance mRNA delivery for cancer immunotherapy,” *Biomaterials* **301** (2023).
- 1129 60. L. Miao, J. Lin, Y. Huang, L. Li, D. Delcassian, Y. Ge, Y. Shi, and D. G. Anderson, “Synergistic lipid compositions
1130 for albumin receptor mediated delivery of mRNA to the liver,” *Nat. Commun.* 2020 11:1 **11**, 1–13 (2020).
- 1131 61. J. Viger-Gravel, A. Schantz, A. C. Pinon, A. J. Rossini, S. Schantz, and L. Emsley, “Structure of Lipid Nanoparticles
1132 Containing siRNA or mRNA by Dynamic Nuclear Polarization-Enhanced NMR Spectroscopy,” *The journal physical*
1133 *chemistry. B* **122**, 2073–2081 (2018).
- 1134 62. L. Schoenmaker, D. Witzgmann, J. A. Kulkarni, R. Verbeke, G. Kersten, W. Jiskoot, and D. J. Crommelin,
1135 “mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability,” *Int. J. Pharm.* **601**, 120586 (2021).
- 1136 63. W. Pezeshkian, M. König, T. A. Wassenaar, and S. J. Marrink, “Backmapping triangulated surfaces to coarse-grained
1137 membrane models,” *Nat. Commun.* 2020 11:1 **11**, 1–9 (2020).
- 1138 64. L. Martinez, R. Andrade, E. G. Birgin, and J. M. Martínez, “PACKMOL: A package for building initial configurations
1139 for molecular dynamics simulations,” *J. Comput. Chem.* **30**, 2157–2164 (2009).
- 1140 65. B. R. Kent, *3D Scientific Visualization with Blender®*, 2053-2571 (Morgan Claypool Publishers, 2015).
- 1141 66. B. M. H. Bruininks, T. A. Wassenaar, and I. Vattulainen, “Unbreaking Assemblies in Molecular Simulations with
1142 Periodic Boundaries,” *J. Chem. Inf. Model.* **63**, 3448–3452 (2023).
- 1143 67. B. M. H. Bruininks, “GitHub - BartBruininks/mdvcontainment: Robust characterization of inside and outside in
1144 periodic spaces. — github.com,” <https://github.com/BartBruininks/mdvcontainment>. [Accessed
1145 01-08-2024].
- 1146 68. W. Humphrey, A. Dalke, and K. Schulten, “VMD: Visual molecular dynamics,” *J. Mol. Graph.* **14**, 33–38 (1996).
- 1147 69. S. L. Leikin, M. M. Kozlov, L. V. Chernomordik, V. S. Markin, and Y. A. Chizmadzhev, “Membrane fusion:
1148 Overcoming of the hydration barrier and local restructuring,” *J. Theor. Biol.* **129**, 411–425 (1987).
- 1149 70. J. Stevens, F. Grünewald, P. van Tilburg, M. König, B. Gilbert, T. Brier, Z. Thornburg, Z. Luthey-Schulten, and
1150 S. Marrink, “Molecular dynamics simulation of an entire cell,” *Front. Chem.* **11** (2023).
- 1151 71. M. D. Andreasen, P. C. T. Souza, B. Schiøtt, and L. Zuzic, “Creating coarse-grained systems with coby: Towards
1152 higher accuracy in membrane complexity,” *bioRxiv* (2024).
- 1153 72. B. M. H. Bruininks, A. S. Thie, P. C. T. Souza, T. A. Wassenaar, S. Faraji, and S. J. Marrink, “Sequential Voxel-Based
1154 Leaflet Segmentation of Complex Lipid Morphologies,” *J. Chem. Theory Comput.* **17**, 7885 (2021).
- 1155 73. O. S. Ollila and G. Pabst, “Atomistic resolution structure and dynamics of lipid bilayers in simulations and experiments,”

- 1156 Biochimica et Biophys. Acta (BBA) - Biomembr. **1858**, 2512–2528 (2016).
- 1157 74. M. Javanainen, P. Hefberger, J. J. Madsen, M. S. Miettinen, G. Pabst, and O. H. S. Ollila, “Quantitative comparison
1158 against experiments reveals imperfections in force fields’ descriptions of popc–cholesterol interactions,” *J. Chem.*
1159 *Theory Comput.* **19**, 6342–6352 (2023). PMID: 37616238.
- 1160 75. J. Lee, D. S. Patel, J. Stähle, S. J. Park, N. R. Kern, S. Kim, J. Lee, X. Cheng, M. A. Valvano, O. Holst, Y. A. Knirel,
1161 Y. Qi, S. Jo, J. B. Klauda, G. Widmalm, and W. Im, “CHARMM-GUI Membrane Builder for Complex Biological
1162 Membrane Simulations with Glycolipids and Lipoglycans,” *J. Chem. Theory Comput.* **15**, 775–786 (2019).
- 1163 76. L. F. Dettmann, O. Kühn, and A. A. Ahmed, “Martini-based coarse-grained soil organic matter model derived from
1164 atomistic simulations,” *J. Chem. Theory Comput.* **20**, 5291–5305 (2024). PMID: 38831535.
- 1165 77. T. Bereau and K. Kremer, “Automated parametrization of the coarse-grained martini force field for small organic
1166 molecules,” *J Chem Theory Comput.* **11**, 2783–2791 (2015).
- 1167 78. K. S. Stroh, P. C. T. Souza, L. Monticelli, and H. J. Risselada, “Cgcompiler: Automated coarse-grained molecule
1168 parametrization via noise-resistant mixed-variable optimization,” *J. Chem. Theory Comput.* **19**, 8384–8400 (2023).
1169 PMID: 37971301.
- 1170 79. G. P. Pereira, R. Alessandri, M. Domínguez, R. Araya-Osorio, L. Grünewald, L. Borges-Araújo, S. Wu, S. J. Marrink,
1171 P. C. T. Souza, and R. Mera-Adasme, “Bartender: Martini 3 bonded terms via quantum mechanics-based molecular
1172 dynamics,” *J. Chem. Theory Comput.* **20**, 5763–5773 (2024). PMID: 38924075.
- 1173 80. C. Empereur-mot, K. B. Pedersen, R. Capelli, M. Crippa, C. Caruso, M. Perrone, P. C. T. Souza, S. J. Marrink, and
1174 G. M. Pavan, “Automatic optimization of lipid models in the martini force field using swarmcg,” *J. Chem. Inf. Model.*
1175 **63**, 3827–3838 (2023). PMID: 37279107.
- 1176 81. M. Palonciová, M. Pykal, P. Kührová, P. Panáš, J. Šponer, and M. Otyepka, “Computer aided development of nucleic
1177 acid applications in nanotechnologies,” *Small* **18**, 2204408 (2022).
- 1178 82. N. Aho, P. Buslaev, A. Jansen, P. Bauer, G. Groenhof, and B. Hess, “Scalable constant ph molecular dynamics in
1179 gromacs,” *J. Chem. Theory Comput.* **18**, 6148–6160 (2022). PMID: 36128977.
- 1180 83. H. A. F. Santos, D. Vila-Viçosa, V. H. Teixeira, A. M. Baptista, and M. Machuqueiro, “Constant-ph md simulations
1181 of dmpa/dmpc lipid bilayers,” *J. Chem. Theory Comput.* **11**, 5973–5979 (2015).
- 1182 84. F. Grünewald, P. C. T. Souza, H. Abdizadeh, J. Barnoud, A. H. de Vries, and S. J. Marrink, “Titratable Martini model
1183 for constant pH simulations,” *The J. Chem. Phys.* **153**, 024118 (2020).
- 1184 85. M. König, R. de Vries, F. Grünewald, S. Marrink, and W. Pezeshkian, “Curvature-induced lipid sorting beyond the
1185 critical packing parameter,” *bioRxiv* (2023).
- 1186 86. J. S. Hub, “Joint reaction coordinate for computing the free-energy landscape of pore nucleation and pore expansion
1187 in lipid membranes,” *J. Chem. Theory Comput.* **17**, 1229–1239 (2021).
- 1188 87. W. D. Bennett and D. P. Tieleman, “Water defect and pore formation in atomistic and coarse-grained lipid membranes:
1189 Pushing the limits of coarse graining,” *J. Chem. Theory Comput.* **7**, 2981–2988 (2011).
- 1190 88. S. M. Lee, Q. Cheng, X. Yu, S. Liu, L. T. Johnson, and D. J. Siegwart, “A systematic study of unsaturation in lipid
1191 nanoparticles leads to improved mrna transfection in vivo,” *Angewandte Chemie Int. Ed.* **60**, 5848–5853 (2021).
- 1192 89. X. Hou, T. Zaks, R. Langer, and Y. Dong, “Lipid nanoparticles for mrna delivery,” *Nat. Rev. Mater.* **6**, 1078–1094
1193 (2021).
- 1194 90. E. Kon, N. Ad-El, I. Hazan-Halevy, L. Stotsky-Oterin, and D. Peer, “Targeting cancer with mrna–lipid nanoparticles:
1195 key considerations and future prospects,” *Nat. Rev. Clin. Oncol.* **20**, 739–754 (2023).
- 1196 91. M. J. Abraham, T. Murtola, R. Schulz, S. Páll, J. C. Smith, B. Hess, and E. Lindah, “Gromacs: High performance
1197 molecular simulations through multi-level parallelism from laptops to supercomputers,” *SoftwareX* **1-2**, 19–25
1198 (2015).
- 1199 92. R. J. Gowers, M. Linke, J. Barnoud, T. J. E. Reddy, M. N. Melo, S. L. Seyler, J. Domanski, D. L. Dotson, S. Buchoux,
1200 I. M. Kenney, and O. Beckstein, “MDAnalysis: A Python Package for the Rapid Analysis of Molecular Dynamics
1201 Simulations,” *Proc. 15th Python Sci. Conf.* pp. 98–105 (2019).
- 1202 93. N. Michaud-Agrawal, E. J. Denning, T. B. Woolf, and O. Beckstein, “MDAnalysis: A toolkit for the analysis of
1203 molecular dynamics simulations,” *J. Comput. Chem.* **32**, 2319–2327 (2011).
- 1204 94. C. R. Harris, K. J. Millman, S. J. van der Walt, R. Gommers, P. Virtanen, D. Cournapeau, E. Wieser, J. Taylor,
1205 S. Berg, N. J. Smith, R. Kern, M. Picus, S. Hoyer, M. H. van Kerkwijk, M. Brett, A. Haldane, J. F. del Río, M. Wiebe,
1206 P. Peterson, P. Gérard-Marchant, K. Sheppard, T. Reddy, W. Weckesser, H. Abbasi, C. Gohlke, and T. E. Oliphant,
1207 “Array programming with NumPy,” *Nat.* 2020 585:7825 **585**, 357–362 (2020).
- 1208 95. J. D. Hunter, “Matplotlib: A 2D graphics environment,” *Comput. Sci. Eng.* **9**, 90–95 (2007).
- 1209 96. S. Buchoux, “FATSLiM: a fast and robust software to analyze MD simulations of membranes,” *Bioinformatics* **33**,
1210 133–134 (2017).
- 1211 97. W. Humphrey, A. Dalke, and K. Schulten, “VMD – Visual Molecular Dynamics,” *J. Mol. Graph.* **14**, 33–38 (1996).
- 1212 98. J. Stone, J. Gullingsrud, P. Grayson, and K. Schulten, “A system for interactive molecular dynamics simulation,” in
1213 *2001 ACM Symposium on Interactive 3D Graphics*, J. F. Hughes and C. H. Séquin, eds. (ACM SIGGRAPH, New
1214 York, 2001), pp. 191–194.
- 1215 99. “Rdkit: open-source cheminformatics,” <https://www.rdkit.org>.
- 1216 100. R. Alessandri, J. Barnoud, A. S. Gertsen, I. Patmanidis, A. H. de Vries, P. C. T. Souza, and S. J. Marrink, “Martini 3
1217 coarse-grained force field: Small molecules,” *Adv. Theory Simulations* **5**, 2100391 (2022).
- 1218 101. R. Alessandri, S. Thallmair, C. G. Herrero, R. Mera-Adasme, S. J. Marrink, and P. C. T. Souza, “A Practical

- 1219 Introduction to Martini 3 and its Application to Protein-Ligand Binding Simulations,” in *A Practical Guide to Recent*
1220 *Advances in Multiscale Modeling and Simulation of Biomolecules*, (AIP Publishing LLC).
- 1221 102. L. S. Dodda, I. C. De Vaca, J. Tirado-Rives, and W. L. Jorgensen, “LigParGen web server: an automatic OPLS-AA
1222 parameter generator for organic ligands,” *Nucleic Acids Res.* **45**, W331–W336 (2017).
- 1223 103. L. S. Dodda, J. Z. Vilseck, J. Tirado-Rives, and W. L. Jorgensen, “1.14*CM1A-LBCC: Localized Bond Charge
1224 Corrected CM1A Charges for Condensed-Phase Simulations,” *The journal physical chemistry. B* **121**, 3864 (2017).
- 1225 104. H. J. C. Berendsen, J. P. M. Postma, W. F. V. Gunsteren, A. Dinola, and J. R. Haak, “Molecular dynamics with
1226 coupling to an external bath,” *The J. Chem. Phys.* **81**, 3684–3690 (1984).
- 1227 105. G. Bussi, D. Donadio, and M. Parrinello, “Canonical sampling through velocity rescaling,” *J. Chem. Phys.* **126**,
1228 14101 (2007).
- 1229 106. M. Parrinello and A. Rahman, “Polymorphic transitions in single crystals: A new molecular dynamics method,” *J.*
1230 *Appl. Phys.* **52**, 7182–7190 (1981).
- 1231 107. T. Darden, D. York, and L. Pedersen, “Particle mesh Ewald: An N-log(N) method for Ewald sums in large systems,”
1232 *The J. Chem. Phys.* **98**, 10089–10092 (1993).
- 1233 108. S. Páll and B. Hess, “A flexible algorithm for calculating pair interactions on SIMD architectures,” *Comput. Phys.*
1234 *Commun.* **184**, 2641–2650 (2013).
- 1235 109. B. Hess, H. Bekker, H. J. C. Berendsen, and J. G. E. M. Fraaije, “LINCS: A Linear Constraint Solver for molecular
1236 simulations,” *J. Comput. Chem.* **18**, 1463–1472 (1997).
- 1237 110. D. H. de Jong, S. Baoukina, H. I. Ingólfsson, and S. J. Marrink, “Martini straight: Boosting performance using a
1238 shorter cutoff and GPUs,” *Comput. Phys. Commun.* **199**, 1–7 (2016).
- 1239 111. C. Bannwarth, S. Ehlert, and S. Grimme, “Gfn2-xtb—an accurate and broadly parametrized self-consistent
1240 tight-binding quantum chemical method with multiple electrostatics and density-dependent dispersion contributions,”
1241 *J. Chem. Theory Comput.* **15**, 1652–1671 (2019).
- 1242 112. C. Bannwarth, E. Caldeweyher, S. Ehlert, A. Hansen, P. Pracht, J. Seibert, S. Spicher, and S. Grimme, “Extended
1243 tight-binding quantum chemistry methods,” *WIREs Comput. Mol. Sci.* **11**, e1493 (2021).
- 1244 113. A. D. Becke, “Density-functional exchange-energy approximation with correct asymptotic behavior,” *Phys. Rev. A*
1245 **38**, 3098–3100 (1988).
- 1246 114. J. P. Perdew, “Density-functional approximation for the correlation energy of the inhomogeneous electron gas,”
1247 *Phys. Rev. B* **33**, 8822–8824 (1986).
- 1248 115. F. Weigend and R. Ahlrichs, “Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence
1249 quality for h to rn: Design and assessment of accuracy,” *Phys. Chem. Chem. Phys.* **7**, 3297–3305 (2005).
- 1250 116. S. Grimme, J. Antony, S. Ehrlich, and H. Krieg, “A consistent and accurate ab initio parametrization of density
1251 functional dispersion correction (DFT-D) for the 94 elements H-Pu,” *The J. Chem. Phys.* **132**, 154104 (2010).
- 1252 117. K. Eichkorn, F. Weigend, O. Treutler, and R. Ahlrichs, “Auxiliary basis sets for main row atoms and transition
1253 metals and their use to approximate coulomb potentials,” *Theor. Chem. Accounts* **97**, 119–124 (1997).
- 1254 118. S. Balasubramani, G. Chen, S. Coriani, M. Diederhofen, M. Frank, Y. Franzke, F. Furche, R. Grotjahn, M. Harding,
1255 C. Hättig, A. Hellweg, B. Helmich-Paris, C. Holzer, U. Huniar, M. Kaupp, A. Marefat Khah, S. Karbalaeei Khani,
1256 T. Müller, F. Mack, B. Nguyen, S. Parker, E. Perlt, D. Rappoport, K. Reiter, S. Roy, M. Rückert, G. Schmitz, M. Sierka,
1257 E. Tapavicza, D. Tew, C. van Wüllen, V. Voora, F. Weigend, A. Wodyński, and J. Yu, “Turbomole: Modular program
1258 suite for ab initio quantum-chemical and condensed-matter simulations,” *The J. Chem. Phys.* **152** (2020).
- 1259 119. J. G. Kirkwood, “Statistical Mechanics of Fluid Mixtures,” *The J. Chem. Phys.* **3**, 300–313 (1935).
- 1260 120. J. L. MacCallum and D. P. Tieleman, “Structures of neat and hydrated 1-octanol from computer simulations,” *J.*
1261 *Am. Chem. Soc.* **124**, 15085–15093 (2002).
- 1262 121. S. E. DeBolt and P. A. Kollman, “Investigation of Structure, Dynamics, and Solvation in 1-Octanol and Its
1263 Water-Saturated Solution: Molecular Dynamics and Free-Energy Perturbation Studies,” *J. Am. Chem. Soc.* **117**,
1264 5316–5340 (1995).
- 1265 122. N. Goga, A. J. Rzepiela, A. H. de Vries, S. J. Marrink, and H. J. Berendsen, “Efficient algorithms for langevin and
1266 DPD dynamics,” *J. Chem. Theory Comput.* **8**, 3637–3649 (2012).
- 1267 123. M. R. Shirts and J. D. Chodera, “Statistically optimal analysis of samples from multiple equilibrium states,” *J.*
1268 *Chem. Phys.* **129** (2008).
- 1269 124. J. B. Lim, B. Rogaski, and J. B. Klauda, “Update of the cholesterol force field parameters in charmm,” *The J. Phys.*
1270 *Chem. B* **116**, 203–210 (2012).
- 1271 125. S. J. Marrink, A. H. de Vries, T. A. Harroun, J. Katsaras, and S. R. Wassall, “Cholesterol shows preference for the
1272 interior of polyunsaturated lipid membranes,” *J. Am. Chem. Soc.* **130**, 10–11 (2008).
- 1273 126. M. N. Melo, H. I. Ingólfsson, and S. J. Marrink, “Parameters for Martini sterols and hopanoids based on a virtual-site
1274 description,” *J. Chem. Phys.* **143** (2015).
- 1275 127. Y. Zhang and E. J. Maginn, “A comparison of methods for melting point calculation using molecular dynamics
1276 simulations,” *J. Chem. Phys.* **136** (2012).
- 1277 128. M. Tsanai, P. J. M. Frederix, C. F. E. Schroer, P. C. T. Souza, and S. J. Marrink, “Coacervate formation studied by
1278 explicit solvent coarse-grain molecular dynamics with the martini model,” *Chem. Sci.* **12**, 8521–8530 (2021).
- 1279 129. H. I. Ingólfsson, A. Rizuan, X. Liu, P. Mohanty, P. C. Souza, S. J. Marrink, M. T. Bowers, J. Mittal, and J. Berry,
1280 “Multiscale simulations reveal tdp-43 molecular-level interactions driving condensation,” *Biophys. J.* **122**, 4370–4381
1281 (2023).

- 1282 130. J. J. Uusitalo, H. I. Ingólfsson, P. Akhshi, D. P. Tieleman, and S. J. Marrink, “Martini coarse-grained force field:
1283 Extension to dna,” *J. Chem. Theory Comput.* **11**, 3932–3945 (2015).
- 1284 131. J. J. Uusitalo, H. I. Ingólfsson, S. J. Marrink, and I. Faustino, “Martini coarse-grained force field: Extension to rna,”
1285 *Biophys. J.* **113**, 246–256 (2017).
- 1286 132. F. Grünewald, M. H. Punt, E. E. Jefferys, P. A. Vainikka, M. König, V. Virtanen, T. A. Meyer, W. Pezeshkian, A. J.
1287 Gormley, M. Karonen, M. S. P. Sansom, P. C. T. Souza, and S. J. Marrink, “Martini 3 coarse-grained force field for
1288 carbohydrates,” *J. Chem. Theory Comput.* **18**, 7555–7569 (2022).
- 1289 133. S. Kumar, J. M. Rosenberg, D. Bouzida, R. H. Swendsen, and P. A. Kollman, “THE weighted histogram analysis
1290 method for free-energy calculations on biomolecules. I. The method,” *J. Comput. Chem.* **13**, 1011–1021 (1992).
- 1291 134. B. M. H. Bruininks, P. C. T. Souza, and S. J. Marrink, *A Practical View of the Martini Force Field* (Springer New
1292 York, New York, NY, 2019), pp. 105–127.
- 1293 135. E. Quemener and M. Corvellec, “SIDUS—the solution for extreme deduplication of an operating system,” *Linux J.*
1294 **2013**, 3 (2013).